26th International Congress of Clinical Chemistry and Laboratory Medicine

17th Congress of Arab Federation of Clinical Biology

10th Saudi Society for Clinical Chemistry Annual Meeting

8th UAEGDA International Genetic Disorders Conference

Dubai World Trade Centre (DWTC) DUBAI - UAE
Dear Colleagues and Friends,

On behalf of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), it is my distinct pleasure and honor to welcome you to the 26th International Congress of Clinical Chemistry and Laboratory Medicine (ICCCML) - IFCC WorldLab Congress organized jointly with the 12th Congress of the Arab Federation of Clinical Biology (AFCB), 10th Annual Meeting of the Saudi Society for Clinical Chemistry (SSCC) and 8th International and United Arab Emirates (UAE) Genetic Disorders Conference in partnership with MZ Events held in Dubai World Trade Centre (WTC) from May 26 to May 30, 2024. WorldLab Congress stands as a pinnacle event within the realm of laboratory medicine, bringing together scientists, researchers, clinicians, and experts from the In Vitro Diagnostics industry for a rewarding five-day experience of scientific exploration and education. The 3rd IFCC FORUM for Young Scientists and IFCC Council meeting are organized before the main Congress.

The Scientific Program Committee has prepared an exceptional, thought-provoking, and inspirational multidisciplinary program encompassing fundamental concepts, advanced diagnostics, and cutting-edge techniques in laboratory medicine. Esteemed international speakers, and key opinion leaders will address various topics including healthcare, recent diagnostic technologies, scientific breakthroughs, and challenges. Renowned for its comprehensive program, the congress features a dynamic array of plenary lectures, symposia, workshops, and poster presentations, covering a wide spectrum of subjects. It serves as a vital platform for collaboration, innovation, and exchange of cutting-edge knowledge within the field.

WorldLab 2024 serves as a platform to showcase the latest technologies and innovations in laboratory medicine and explore their potential applications in healthcare. This gathering fosters collaboration among researchers and clinicians, ultimately advancing patient care and outcomes. The Congress is accredited by the EFLM CPECS®, a quality assurance mechanism to provide Continuing Professional Development for participants.

My heartfelt thanks for In Vitro Diagnostic Sector, their continuous support and contribution have made possible the accomplishment of this Congress. The In Vitro Diagnostic (IVD) Sector plays a vital role in the Congress by organizing two essential activities. High-level Educational Workshops on important topics with eminent speakers presenting the latest scientific advances in all disciplines relevant to laboratory medicine. The IVD Sector also organizes a great exhibition, providing attendees with a prime opportunity to explore recent technological advancements, products, and services aimed at enhancing laboratory operations. These customized solutions address the specific requirements of clinical laboratories, ensuring attendees acquire valuable insights and access to state-of-the-art tools in the field.

The objective of this meeting is not only to contribute to the advancement of laboratory medicine and to the dissemination of advanced knowledge, but also to foster the creation of an opportunity to establish professional and scientific links/bridges among the participants.

I would like to extend our gratitude and thanks to all those who have made it possible for this congress to become a reality, especially I would like to thank all the eminent speakers, IVD industry representatives, and all the participants attending the Congress from different countries all around the world. I would like to thank the Professional Congress Organizer (MZ) for their efforts to organize the congress successfully.

I extend my heartfelt wishes to all participants for a delightful stay in Dubai, where the 26th WorldLab promises to be an unforgettable congress. It offers an extraordinary opportunity to engage with leading experts and scientists, enjoy an inspiring scientific program, explore the exhibition, and take part in networking and social activities. May your time here be both rewarding and worthwhile.

Prof. Tomris Ozben
EuSpLM, Ph.D., Full Professor of Clinical Biochemistry
IFCC, President
WorldLab Dubai 2024,
Congress President
It gives me immense pleasure to extend a warm welcome to all participants of the XXVI IFCC WorldLab Congress, jointly hosted by the IFCC, Arab Federation of Clinical Biochemistry, Saudi Society of Clinical Chemistry, and the UAE Genetics Association. This marks the inaugural occasion of WorldLab being held in the Middle East, congregating experts from across the globe in the vibrant city of Dubai, now recognized as one of the world’s most dynamic and technologically advanced cities. The 2024 WorldLab Congress will unite laboratory professionals and scientists from the UAE, various Arab Federation countries, and other regional federations within IFCC including Africa, Europe, North America, Central/South America, and Asia-Pacific. Anticipated to be the most successful IFCC WorldLab outside Europe, this event arrives at a pivotal moment in the evolution of clinical chemistry and laboratory medicine. We are amidst significant scientific and technological progressions, empowering our professionals to play an increasingly pivotal role in healthcare.

This timely congress provides an exceptional platform for international discourse on these advancements and facilitates collaboration among peers. The biannual WorldLab congress has consistently served as a premier forum, fostering dialogue among scientists, laboratory specialists, clinicians, and industry professionals in the field. Such gatherings facilitate scientific exchange, ensuring that our organization and the field of clinical chemistry and laboratory medicine remain at the forefront of innovation.

Throughout the congress, attendees will engage in a stellar scientific program, featuring a diverse range of educational opportunities encompassing the latest developments in clinical laboratory medicine and in vitro diagnostics. From lectures and symposia to poster presentations, the program promises to be both innovative and comprehensive. Notably, a significant focus will be placed on technological advancements, aiming to bridge the gap between cutting-edge diagnostic laboratory technology and clinical practice.

Beyond the scientific agenda, Dubai offers a cosmopolitan backdrop, providing ample opportunities for social engagement and exploration. I trust that you will relish both the enriching scientific discourse curated by the organizing and scientific committees, as well as the vibrant social experiences awaiting you in Dubai.

I extend my best wishes to all of you for a memorable stay in Dubai and look forward to seeing and meeting many of you soon!

Prof. Khosrow Adeli
Co-Chair
Congress Organizing Committee
Past President, IFCC

Dear esteemed attendees,

As a co-chair of the 26th WorldLab Meeting of the International Federation of Clinical Chemistry (IFCC), I am delighted to extend a warm welcome to all participants of the upcoming event in the Arab world for the first time. The meeting will be jointly hosted with the 17th Arab Federation of Clinical Biology (AFGB), the 10th Annual meeting for the Saudi Society for Clinical Chemistry (SSCC), and the 8th UAE Genetic Disorders Conference, in cooperation with the Emirates Clinical Chemistry Society (ECCS).

For this event, the scientific committee worked hard to create an exciting program covering the most relevant and recent aspects of clinical laboratory medicine and patient care. To achieve this, outstanding local and international experts in clinical laboratory were selected as speakers and moderators for the scientific program. This will provide an opportunity to develop new personal relationships within the region and other parts of the world, facilitating the exchange of experience, knowledge, and skills.

We are pleased to announce that this year’s meeting has received more than 1600 accepted abstracts from all over the world. This number reflects the enthusiasm of laboratory professionals to engage in the event.

As we gather in Dubai for the IFCC meeting, let us take advantage of this unique opportunity not only to enrich the scientific discussions but also to explore and experience all that this remarkable city has to offer. Dubai, where innovation meets tradition, offers a wealth of attractions and experiences during the stay of our attendees, including its cultural heritage, world-class amenities, warm hospitality, and accessibility from all over the globe.

SSCC is dedicated to making Worldlab 2024 an unforgettable meeting for all attendees, and I look forward to welcoming you to Dubai for what promises to be an unforgettable experience.

Warm regards,

Prof. Anwar Borai
Co-Chair
IFCC Worldlab 2024
SSCC Representative to the IFCC
Dear attendees, colleagues, and friends,

Welcome to IFCC Worldlab 2024 in Dubai, an event organized jointly with the Arab Federation of Clinical Biology, the Saudi Society for Clinical Chemistry, and the United Arab Emirates Genetic Diseases Association. This promising partnership heralds new insights in the field of biology, fostering collaborations and exploring new horizons. It’s the first time such a congress is held in an Arab country, and everything has been orchestrated to ensure its tremendous success. This collaboration between nations aims to exchange expertise and knowledge, while also providing young individuals the opportunity to explore their future careers, gain valuable insights, and forge professional networks that will enable collaborative work across various countries.

We take pride in the enthusiastic hosting of this event by the Arab countries, accompanied by active participation from their scientists in various activities. This congress aims to open a window to the international community for our colleagues from the Arab world. The venue for this congress is no ordinary one. Dubai, a true melting pot of cultures, provides the perfect backdrop for the emergence of brilliant enterprises and futuristic projects. Beyond its unparalleled tourist attractions, Dubai embodies a bustling hive, working tirelessly to make this corner of the world a platform for a different worldview, uniting people from around the globe driven by the need for peace, stability, and a desire to contribute positively to society. This is complemented by the traditional Arab hospitality, making everyone feel at home in a country known for its warmth and welcoming nature.

As we embark on this journey together, let us seize the opportunities presented by this congress to exchange knowledge, forge collaborations, and chart a course towards a future where healthcare knows no bounds. The IFCC, Saudi Arabia, the United Arab Emirates, and all Arab countries join together to wish everyone a successful congress, fostering a sense of fraternity in a world torn apart by wars and intolerance. Let us gather here for a better world, improved patient care, and a bright future for our profession. And may this congress be a catalyst for transformative change, empowering us all to make significant strides in the realm of clinical biology.

Christian Haddad

President Arab Federation of Clinical Biology

Message

Dr. Christian Haddad
President Arab Federation of Clinical Biology (AFCB)

Dear Esteemed Attendees, Colleagues, and Friends,

Please allow me to extend my warmest welcome to Dubai, UAE, for the first International Federation of Clinical Chemistry (IFCC) WorldLab conference in the Middle East. It is our sincere honor to co-host this event with the Saudi Society for Clinical Chemistry (SSCCI) in partnership with the IFCC and the Arab Federation of Clinical Biochemistry (AFCB). Together, we have delivered a dynamic program that offers a unique blend of insights across academia and industry. We are thrilled to welcome to our stage, renowned speakers from a wide variety of disciplines. For our UAEGDA sessions, we have intentionally focused on spotlighting talent within the UAE, as well as supporting our international friends.

On this special occasion, the UAEGDA celebrates its 20th Anniversary, a fitting event to highlight our continued commitment to our mission. We nurture innovation and education to prevent challenges faced by individuals with genetic disorders in the UAE and the region. At present, the medical field is ever evolving and changing at a rapid pace. Now is the time to focus and understand the future of Medicine. With new technologies emerging, and paving the way for breakthrough after breakthrough, we must keenly share our findings for the benefit of humankind.

We cannot wait to share our knowledge and city with you, as we embark on this exciting journey of learning and growth!

Our vibrant city of Dubai awaits you!

Dr. Maryam bin Matar, M.D, PhD

Chairperson UAE Genetic Diseases Association

Message

Dr. Maryam bin Matar,
M.D, PhD,
Founder and Chairperson of UAE Genetic Disease Association
We are delighted to welcome you at the IFCC WorldLab in Dubai from May 26 through May 30, 2024. Along with the organizing committee, the scientific program committee for the conference is eager to create a stimulating scientific agenda that covers the most important trends and innovations in clinical laboratory medicine and patient care. The fundamental goal of the conference has been to globalize medical knowledge in Clinical Chemistry and Laboratory Medicine through a carefully structured system of ongoing scientific education. The Scientific Committee worked hard to create an amazing, challenging, and inspiring program. A scientific program addressing the present and future developments in clinical laboratory science, novel emerging lab technologies, updated diagnostic methodologies, discussion of global health issues, contemporary quality applications, and digitalization of clinical laboratories. The congress will provide lots of educational opportunities as renowned international speakers, inventors and innovators will update you on the state-of-science in laboratory medicine. Attendees will enjoy an amazing scientific program. The titles and speakers of the plenaries are displayed; the symposia are balanced and will specifically cover the themes of Emerging Technologies & Biomarkers, Data Science and Medical Leadership, among others. These educational opportunities will combine the best of clinical laboratory medicine and in vitro diagnostics. The congress will provide the attendees opportunity to make significant improvements, refresh their scientific knowledge with our excellent specialists, and build new personal ties within the area and throughout the world via the sharing of experience, information, and skills. As well, the congress will promote the development of Clinical Chemistry and Laboratory Medicine. We sincerely hope you will have the opportunity to exchange experiences, to network, and to participate in the most cutting-edge research in laboratory medicine.

All of our international and national participants attending IFCC WorldLab will undoubtedly have a rewarding and memorable experience.

Professor Christa Cobbaert
Dr Samia Sobki
Scientific Program Committee co-Chairs

Weber Diagnostic

Smaller Footprint
Higher Efficiency
Total Laboratory Automation Solutions

SATLARS™-T8

Efficiency  Flexibility  Intelligence  Compatibility

May 26-30, 2024
Dubai World Trade Centre Booth No.: 8
COMMITTEES

Conference Organizing Committee (COC)
Tomris Ozben, Congress President
Khosrow Adeli, Co-Chair
Anwar Borai, Co-Chair
Paivi Laitinen
Alexandre Haliassos
Samia Sobki
Christa Cobbaret
Christian Haddad
Osama Najjar
Maryam Matar
Angel De La Fuente
Vincent Chen
Stefano Montalbetti

Scientific Program Committee (SPC)
Samia Sobki, Co-Chair
Christa Cobbaret, Co-Chair
Salam Saadaddin
Nader Rifai
Mario Plebani
Abderrazek Hedhili
Myrna Germanos Haddad
Santiago Fares Taie
Shaikha Almazrouei

International Scientific Advisory Board (ISAB)
Anna Carobene (EFLM)
Snezana Jovicic (EFLM)
Michel Langlois (EFLM)
Abdulrahman Koskun (EFLM)
Timo Kouri (EFLM)
Tze-Ping Loh (APFCB)
Endang Hoyeranda (APFCB)
Tony Badrick (APFCB)
Bolonghoge Dayanath (APFCB)
Leslie Lai (APFCB)
José Francisco Muñoz-Valle (COLABIOCLI)
Marlene Velez de la Vega (COLABIOCLI)
Cecilia Tapia Paredes (COLABIOCLI)
Cristina Servetto (COLABIOCLI)
Alvaro Justiniano Grosz (COLABIOCLI)
Rajiv Erasmus (AFCC)
Adekunle Alotaibi (AFCC)
Tahir Pillay (AFCC)
Vanessa Steenkamp (NAFCC)
Stacy E. Melanson (NAFCC)
Qing Meng (NAFCC)
AbdulRazaq A. H. Sokoro (NAFCC)
Alison Woodworth (NAFCC)

United Arab Emirates (UAE) Advisory Group to COC & SPC
Hady Elkhdodary
Aaron Han
Rita Tanios
Laila Abdel Wareth
Fayha Salah Ahmed
Rana Nabulsi
Jyoti Shetye
Mahammad Althahyabat

IFCC Executive Board
Tomris Ozben, President
Khosrow Adeli, Past President
Sergio Bernardini, Secretary
Alexander Haliassos, Treasurer
Tricia Ravalico, Corporate Representative
Rajiv Erasmus, African Federation of Clinical Chemistry (AFCC)
Osama Najjar, Arab Federation of Clinical Biology (AFCB)
Tony Badrick, Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB)
Mario Plebani, European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Eduardo Freggiaro, Latin-American Confederation of Clinical Biochemistry (COLABIOCLI)
David Grenache, North American Federation of Clinical Chemistry and Laboratory Medicine (NAFCC)

AFCB Board
Christian Haddad, President
Imad Itani, Honorary President
Abderrazek Hedhili, Vice-President
Osama Najjar, Past-President
Toumi Benjelloun, General Secretary
Akil Zoghaib, Treasurer
Imad Fadl-Elmulia, Scientific Committee President
Youssef Bitto, Member
Abdelhalim Chachou, Member
Aayad Abbud, Member
Adnan Al-Khaja, Member
Samia Sobki, Member

SSCC Board
Samia Hasan Sobki, President
Ali Fahad Alotaibi, Vice President
Nawaf Dakhelalat Alotaibi, Treasurer
Zuhair Ahmed Awad, Secretary of the Board
Salam Mohammed Saaddeen, Member Board
Waleed Saleh Alotaibi, Member Board
Ali Mohammed Alshangity, Member Board
Khali Khalaf Ataiha, Member Board
Malak Ataallah Almashali, Member Board
## IFCC WORLDLAB 2024

### MONDAY 27 MAY 2024

<table>
<thead>
<tr>
<th>Room</th>
<th>Session</th>
<th>Time</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E</td>
<td>IFCC SYM 1</td>
<td>09.00-11.00</td>
<td>Present and future of chronic kidney disease and acute kidney injury detection</td>
</tr>
<tr>
<td>A</td>
<td>SYM 1</td>
<td>09.00-11.00</td>
<td>The promise of -omics biomarkers</td>
</tr>
<tr>
<td>B</td>
<td>EFLM SYM</td>
<td>09.00-11.00</td>
<td>Metabolic diseases in Arabic countries</td>
</tr>
<tr>
<td>C</td>
<td>WASPALM</td>
<td>09.00-11.00</td>
<td>The role of clinical laboratory in the development of new drugs</td>
</tr>
<tr>
<td>D</td>
<td>SYM 2</td>
<td>09.00-11.00</td>
<td>Apatmers based diagnostic for biomedical applications</td>
</tr>
<tr>
<td>F</td>
<td>SYM 1</td>
<td>09.00-11.00</td>
<td>The promise of -omics biomarkers</td>
</tr>
<tr>
<td></td>
<td>SYM 2</td>
<td>09.00-11.00</td>
<td>Apatmers based diagnostic for biomedical applications</td>
</tr>
<tr>
<td></td>
<td>EFLM SYM</td>
<td>09.00-11.00</td>
<td>Metabolic diseases in Arabic countries</td>
</tr>
<tr>
<td></td>
<td>WASPALM</td>
<td>09.00-11.00</td>
<td>The role of clinical laboratory in the development of new drugs</td>
</tr>
<tr>
<td></td>
<td>SYM 3</td>
<td>11.30-12.30</td>
<td>The potential of single cell and spatial biology</td>
</tr>
<tr>
<td></td>
<td>SYM 4</td>
<td>11.30-12.30</td>
<td>On the way to cardiovascular precision diagnostics</td>
</tr>
<tr>
<td></td>
<td>SYM 5</td>
<td>11.30-12.30</td>
<td>Regulatory challenges for lab-developed tests</td>
</tr>
<tr>
<td></td>
<td>SYM 6</td>
<td>11.30-12.30</td>
<td>Digital competence and artificial intelligence</td>
</tr>
</tbody>
</table>

### TUESDAY 28 MAY 2024

<table>
<thead>
<tr>
<th>Room</th>
<th>Session</th>
<th>Time</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E</td>
<td>IFCC SYM 3</td>
<td>09.00-11.00</td>
<td>The potential of single cell and spatial biology</td>
</tr>
<tr>
<td>A</td>
<td>SYM 4</td>
<td>09.00-11.00</td>
<td>On the way to cardiovascular precision diagnostics</td>
</tr>
<tr>
<td>B</td>
<td>SYM 5</td>
<td>09.00-11.00</td>
<td>Regulatory challenges for lab-developed tests</td>
</tr>
<tr>
<td>C</td>
<td>SYM 6</td>
<td>09.00-11.00</td>
<td>Digital competence and artificial intelligence</td>
</tr>
<tr>
<td>D</td>
<td>SYM 1</td>
<td>09.00-11.00</td>
<td>The promise of -omics biomarkers</td>
</tr>
<tr>
<td>F</td>
<td>SYM 2</td>
<td>09.00-11.00</td>
<td>Apatmers based diagnostic for biomedical applications</td>
</tr>
<tr>
<td></td>
<td>SYM 3</td>
<td>11.30-12.30</td>
<td>The potential of single cell and spatial biology</td>
</tr>
<tr>
<td></td>
<td>SYM 4</td>
<td>11.30-12.30</td>
<td>On the way to cardiovascular precision diagnostics</td>
</tr>
<tr>
<td></td>
<td>SYM 5</td>
<td>11.30-12.30</td>
<td>Regulatory challenges for lab-developed tests</td>
</tr>
<tr>
<td></td>
<td>SYM 6</td>
<td>11.30-12.30</td>
<td>Digital competence and artificial intelligence</td>
</tr>
</tbody>
</table>

### EXHIBITION HALL
- **10.00 - 17.30** Exhibition open
### Wednesday 29 May 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Room E</th>
<th>Room A</th>
<th>Room B</th>
<th>Room C</th>
<th>Room D</th>
<th>Abu Dhabi B</th>
<th>Room F</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>IFCC Symposium 5: Biomarkers for neurodegenerative diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>SYM 7: Meeting the challenge of demonstrating value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SYM 8: How to improve access to lab testing in middle &amp; low-income countries?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AFCB Symposium 2: Epidemic and pandemic infectious in Arabic regions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SYM 9: Healthcare delivery in the 21st century and the role of the clinical laboratory</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>COLAbioCLISYM: Emerging and re-emerging diseases in Latin America</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:15-11:00</td>
<td>UAEGDA: Genomics of rare diseases I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room E</th>
<th>Room A</th>
<th>Room B</th>
<th>Room C</th>
<th>Room D</th>
<th>Abu Dhabi B</th>
<th>Room F</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>PL 3: Obesity: novel developments in diagnostics of underlying causes and treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Poster Session</td>
<td>Lunch</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Poster Session</td>
<td>Lunch</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>WORKSHOP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>UAEGDA: Genetics for Non-Gene</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>NAFC Symposium 1: Laboratory medicine advancing global health across the lifespan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>EDUW 17: SNIBE Looking beyond the future of Laboratory Medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>UAEGDA: Genomics of rare diseases II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>AFCC Symposium 10: Toxicology environmental and health effects</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15-17:00</td>
<td>UAEGDA: Genomics of rare diseases III</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Thursday 30 May 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Room E</th>
<th>Room A</th>
<th>Room B</th>
<th>Room C</th>
<th>Room D</th>
<th>Abu Dhabi B</th>
<th>Room F</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>SYM 11: Circulating cancer biomarkers: quo vadis?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>SYM 12: Preventing kidney disease using advanced urine screening and kidney damage markers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SSCC Symposium 2: Dysglycemia - novel biomarkers for diagnosis and monitoring prognosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SYM 13: Performance specifications of medical tests based on clinical outcome studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SYM 14: Utilization management and successful approaches to change and improve test requesting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>UAE Symposium 2: AI &amp; machine learning applications in laboratory medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:15-10:45</td>
<td>UAEGDA: Global health AI: uniting nations for genomic insights and data governance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45-11:30</td>
<td>UAEGDA: Panel: genomics in the metaverse</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room E</th>
<th>Room A</th>
<th>Room B</th>
<th>Room C</th>
<th>Room D</th>
<th>Abu Dhabi B</th>
<th>Room F</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>PL 4: Making molecular diagnostics faster</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Poster Session</td>
<td>Lunch</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Closing Ceremony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**EXHIBITION HALL** 10:00 - 17:30 Exhibition open
IFCC WorldLab 2024 is accredited!

EFLM Continuing Professional Education Credit System - CPECS®

The 26th International Congress of Clinical Chemistry and Laboratory Medicine (IFCC), the 17th Congress of Arab Federation of Clinical Biology, the 10th Saudi Society for Clinical Chemistry Annual Meeting and the 8th UAE GDA International Disorders Conference are accredited by the EFLM CPECS® to deliver CPECS® credits for participants.

EFLM CPECS® is an administrative system that provides a quality assurance mechanism for the accreditation of continuing education programs and events offered based on high-quality continuing education content in laboratory medicine and relevant scientific topics.

In those countries where a national crediting system is not in place, the CPECS® system can directly represent the system adopted at national level for the certification of the educational events and may recognize CPECS® credits on a voluntary basis.

Breakdown of credits
A maximum of 19.5 CPECS® credits can be awarded for the educational sessions of the IFCC WorldLab 2024. Each participant has to attend at least 75% of each session to get CPECS® credits.

A board with a specific QR code will be placed inside each conference room. Each delegate interested in getting the CPECS® credits must scan the QR code at the entrance and at the exit of the room for every session. In order to scan the QR code the delegate has to use the dedicated Congress APP where a section will be entirely dedicated to the CPECS program.

Once the congress is over, only delegates with 75% of attendance will receive a specific email with the evaluation questionnaire for the sessions they attended.

At the end of the whole process, they will automatically receive the CPECS® certificate.

Delegates from Saudi Arabia who are interested in obtaining CME units (Accredited by the SCFHS) should adhere to the same guidelines set for CPECS credits.

At the end of the Congress, in order to get SCFHS CME credits, please send your request to SSCC email info.sccc.sa@gmail.com and send a scanned copy of your certificate of attendance together with your SCFHS registration number. Requests must be sent within 6th June at the latest.

SUNDAY 26 MAY 2024

Opening Ceremony

17:00-19:00
ROOM E

Welcome addresses
IFCC and Congress President, T. Ozben
Chairs of the Organizing Committee, K. Adeli, A. Borai
AFCB President, C. Haddad
SSCC President, S.H. Sobki
UAE GDA Chairperson, M. Matar

IFCC Awards announced by T. Ozben

Opening Lecture
Chair: T. Ozben (Turkey)
Pushing forward the frontier of cfDNA diagnostics
Dennis Lo (Hong Kong, China)

Professor Dennis Lo is the Li Ka Shing Professor of Medicine of The Chinese University of Hong Kong (CUHK)

His research interests focus on the biology and diagnostic applications of cell-free nucleic acids in plasma. In particular, he discovered the presence of cell-free fetal DNA in maternal plasma in 1997 and has since then been pioneering non-invasive prenatal diagnosis using this technology. This technology has been adopted globally and has created a paradigm in prenatal medicine. He has also made many innovations using circulating nucleic acids for cancer detection, including the screening of early stage nasopharyngeal cancer.

In recognition of his research, Professor Lo has been elected as Fellow of the Royal Society, Foreign Associate of the US National Academy of Sciences, Fellow of The World Academy of Sciences (TWAS) and Founding Member of the Academy of Sciences of Hong Kong.

Professor Lo has won numerous awards, including the 2014 King Faisal International Prize in Medicine, the 2016 Future Science Prize in Life Science, the 2019 Fudan-Zhongzi Science Award, the 2021 Breakthrough Prize in Life Sciences, the 2021 Royal Medal, the 2021 ESHG Mendel Award, the 2022 ISPD Pioneer Award and the 2022 Lasker-DeBakey Clinical Medical Research Award.
MONDAY 27 MAY 2024

IFCC SYMPOSIUM 1

09:00-11:00  ROOM E
PRESENT AND FUTURE OF CHRONIC KIDNEY DISEASE AND ACUTE KIDNEY INJURY DETECTION

Chairs: Joe M. El-Khoury, Rajeevan Selvaratnam

Updates on new eGFR equations and acute kidney injury definitions, Joe M. El-Khoury
An update on albuminuria as a chronic kidney disease marker, Joris Delanghe
Everything is acute until it becomes chronic – biomarkers of kidney injury, Rajeevan Selvaratnam
Using machine learning methods and leveraging electronic health records for acute kidney injury detection and management, Lama Ghazi

Credits: 2 CPECS®

Joris Delanghe (Belgium), Joe M. El-Khoury (USA), Rajeevan Selvaratnam (Canada), Lama Ghazi (UK)

SYMPOSIUM 1

09:00-11:00  ROOM A
THE PROMISE OF - OMICS BIOMARKERS

Chairs: Hans Jacobs, Sergio Bernardini

Glycomics and glycoproteomics: a new biomarker domain debuts in translational research, Manfred Wuhrer
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry, Hans Jacobs
Integration of artificial intelligence and plasma steroidomics with Laboratory Information Management Systems: application to primary aldosteronism, Graeme Eisenhofer
Generative AI as a catalyst for precision medicine research: bridging potential with reality, Zeina Al-Mahayri
Deciphering Biological Impact of Nitrous Oxide Abuse: Insights from Targeted Metabolomics Analysis, Emeline Gernez, Guillaume Grzych

Credits: 2 CPECS®

Hans Jacobs (the Netherlands), Sergio Bernardini (Italy), Manfred Wuhrer (the Netherlands), Graeme Eisenhofer (Germany), Zeina Al-Mahayri (Syria), Emeline Gernez (France), Guillaume Grzych (France)

SYMPOSIUM 2

09:00-11:00  ROOM ABU DHABI B
APTAMERS BASED DIAGNOSTIC FOR BIOMEDICAL APPLICATIONS

Chairs: Mohammed Zourob, Rajiv T. Erasmus

Development of diagnostics for SARS-CoV-2 with high-affinity DNA aptamers, Yingfu Li
Continuous, real-time drug measurements in situ in the living body, Kevin Plaxco
Development of rapid and low-cost aptamer biosensors for biomedical applications, Mohammed Zourob
Aptamer-based label-free electrochemical biosensors for the diagnosis of sickle cell anemia, Wjdan Arishi
Molecular mouse gram-negative resistance cartridges are a valid option for rapid antibiotic resistance detection in blood culture bottles, Veronica Seija

Credits: 2 CPECS®

Mohammed Zourob (Saudi Arabia), Rajiv T. Erasmus (South Africa), Yingfu Li (Canada), Kevin Plaxco (USA), Wjdan Arishi (Saudi Arabia), Veronica Seija (Uruguay)

AFCB SYMPOSIUM 1

09:00-11:00  ROOM C
METABOLIC DISEASES IN ARABIC COUNTRIES

Chairs: Myrna Germanos, Adnan Alkhatib

Rare genetic diseases in the MENA region, Andre Megarbane
Inborn errors of immunity in highly consanguineous populations: from diagnosis to intervention, Mohamed Ridha Barbouche
Epidemiology of the lysosomal storage disorders (LSDs) IN NORTH Africa, Layachi Chabraoui
Overweight and Obesity: the Weight of Genes, Mohamed Makrelouf

Credits: 2 CPECS®

Myrna Germanos (Lebanon), Adnan Alkhatib (Syria), Andre Megarbane (Lebanon), Mohamed Ridha Barbouche (Bahrain), Layachi Chabraoui (Morocco), Mohamed Makrelouf (Algeria)
WASPaLM SESSION

09:00-11:00 ROOM D

THE ROLE OF CLINICAL LABORATORY IN THE DEVELOPMENT OF NEW DRUGS
Chairs: Roberto Verna, Veronica Seija

The Laboratory in Clinical Research, Roberto Verna
The Role of Microbiota in Human Health, Luigina Romani
Revolutionizing Antibiotic Strategies: The Power of Innovative Technologies, Veronica Seija

Credits: 2 CPECS®

EFLM SESSION

09:00-11:00 ROOM B

GREEN LABS. IMPLEMENTING SUSTAINABLE PRACTICES IN MEDICAL LABORATORIES
Chairs: Tomris Ozben, Snezana Jovicic

Green labs: Implementing sustainable practices in medical laboratories, Tomris Ozben
Striking the Right Balance: Sustainability and Innovation, Ffion Jackson
Strategies for energy conservation and sustainability, Snezana Jovicic
Waste management for clinical laboratories, Alistair Gammie

Credits: 2 CPECS®

UAEGDA SESSION

LONGEVITY: DIET & SMART AGING I
Chairs: Mishkat Shehata, Jaffer Khan, Maryam Matar

09:15 - 09:30 Mediterranean diet & the prevention of cardiovascular disease, Samia Mora
09:30 - 09:45 Glycans are modifiable biomarkers and functional effectors of age-related diseases, Gordon Lauc
09:45 - 10:00 Healthy Longevity Medicine: Restoring and maintaining biological age of optimal performance, Evelyne Bischof
10:00 - 10:15 The role of membrane lipidome in lifespan: why dietary lipids can impact on longevity, Vincenzo Di Donna
10:15 - 10:30 Novel strategies to delay brain aging and cognitive decline, David Vazour

Credits: 1 CPECS®

LONGEVITY: DIET & SMART AGING II
Chairs: Mishkat Shehata, Jaffer Khan, Maryam Matar

10:30 - 10:45 Fasting: The Fountain of Youth?, Mussaad Al-Razouki
10:45 - 11:00 Why Longevity Fails – Invisible toxic Exposures, Andrew Jeremijenko

Credits: 0.5 CPECS®
Dr. Mora is a cardiologist and molecular epidemiologist conducting translational research in the prevention of cardiometabolic disease. She is Professor of Medicine at Harvard Medical School, the Director of the Center for Lipid Metabolomics and Director of the Biorepository, Divisions of Preventive and Cardiovascular Medicine, Brigham and Women’s Hospital. She received her undergraduate degree from Harvard University, and her medical degree from Harvard Medical School. Dr. Mora completed an internal medicine residency at Massachusetts General Hospital and cardiovascular disease fellowship at Johns Hopkins Hospital, where she also obtained an MHS degree in Epidemiology from the Johns Hopkins Bloomberg School of Public Health. Dr. Mora is board certified in cardiovascular disease and echocardiography, and serves on the Editorial Boards of JAMA Internal Medicine and Atherosclerosis. She is an Elected Member of the American Society for Clinical Investigation and the Association of University Cardiologists.

Credits: 1 CPECS®
**UAEGDA SESSION**

**16:15 - 17:00 ROOM F**

**PANEL DISCUSSION - LONGEVITY & SMART AGING**

Chairs: Evelyne Bishof, Mussaad Al-Razouki, Saba Habibollah

16:15 - 17:00 Panel discussion

David Vauzour, Jaffer Khan, Andrew Jeremijenko, Andrew McCombe, Mishkat Shehata

**Credits: 0.5 CPECS®**

Evelyne Bishof (Switzerland)

Mussaad Al-Razouki (UAE)

Saba Habibollah (UAE)

David Vauzour (UK)

Jaffer Khan (UAE)

Andrew Jeremijenko (UAE)

Andrew McCombe (UAE)

Mishkat Shehata (UAE)

**IFCC SYMPOSIUM 2**

**14:30-16:30 ROOM E**

**FLOWCYTOMETRY PRINCIPLES AND ITS ROLES IN PRECISION MEDICINE**

Chairs: Claude Lambert, Heba Raslan

Principle of flow cytometry and issues in diagnosis, Claude Lambert

FCM in characterizing lymphoproliferative disorders, Mohamed Brahimi

FCM in diagnosis of immunological disorders and biotherapies, Najla Metkhi

FCM in characterizing acute leukemic disorders, Heba Raslan

**Credits: 2 CPECS®**

Claude Lambert (France)

Heba Raslan (Saudi Arabia)

Mohamed Brahimi (Algeria)

Najla Metkhi (Tunisia)

**SYMPOSIUM 3**

**14:30-16:30 ROOM D**

**THOUGHTS ON MAINTAINING INNOVATION AND AVAILABILITY OF MEDICAL TESTS OR HOW TO MEET REGULATORY CHALLENGES FOR LAB-DEVELOPED-TESTS**

Chairs: Michael Neumaier, Alexander Halassisos

Regulatory considerations for Laboratory-Developed Tests from an international perspective: Opportunities and risks for patient care, Folker Spitzenberger

Impact of diagnostic regulations on laboratory developed tests in the US, Tina Lochwood

Off-label Diagnostics - an analogy to individualized therapeutic medicine: the oncology case, Michael Neumaier, Ralf Hofheinz

Laboratory medicine and integrated diagnostics: the role of information technology, Mario Plebani

**Credits: 2 CPECS®**

Michael Neumaier (Germany)

Alexander Halassios (Greece)

Folker Spitzenberger (Germany)

Tina Lochwood (USA)

Ralf Hofheinz (Germany)

Mario Plebani (Italy)
Convergence of Clinical Diagnostics and Population Health.
Evolving to Clinical Lab 2.0, from Business of Volume to Business of Value.

CHAIR: Els Melis
SPEAKER: Khosrow R. Shotorbani, MBA, MT (ASCP)

PROGRAMME
13:00-13:05: Chair: Welcome and Introduction of the topic and speaker
13:05-13:40: Speaker: Reshaping together how healthcare is delivered.
Evolving the lab from volume to value-based testing.
13:40-14:05: All: Q&A
14:05-14:15: Chair: Close

Learning Objectives:
• Inspire Laboratory Professionals about the future role of the Clinical Laboratory through amplification of actionable insights. The value of the lab doesn’t end when we release a result, rather, that’s where it begins.
• Create a disruptive value paradigm and explore alternative business models that expand the role of diagnostic services in the future healthcare ecosystem.
• Provide a potential platform with specific examples about the convergence of diagnostics and population health.

Background on the topic:
• The role of clinical diagnostics in the sustainable healthcare future state is crucial. As the healthcare moves from volume to value, our healthcare systems require the information to predict and monitor to proactively manage and mitigate clinical risk.
• The longitudinal clinical lab data are essential ingredients to proactively risk stratify the population in preparation to value-based care.
• This is the role of Clinical Lab 2.0!
Educational Workshop 4
14.30 - 15.30 ROOM B

Simpler, Smarter Solutions: Waters Total LC-MS/MS Workflow

SPEAKER 1: Godo BOSCH
SPEAKER 2: Stephen BALLOCH

PROGRAMME:
Why LC/MS is becoming essential in the Diagnostic Laboratory (25 min)
Recent developments to simplify and improve efficiency of the workflow for complex and emerging applications (35 min)
Includes time for Questions and Answers

Learning Objectives:
The ever-growing use of mass spectrometry (MS) in clinical diagnostics has resulted in the introduction of numerous methods information rich with high sensitivity and unrivalled specificity. Numerous disease areas have benefited enormously from clinical MS development. MS methods are becoming routine and are preferred techniques in many clinical laboratories for specific patient cohorts.

This session is aimed at giving insights into different MS applications that help to resolve challenging analytical demands for specific patient cohorts and how this can support diagnostics, monitoring and eventually, disease prevention.

Examples in routine work such as Endocrinology and Therapeutic Drug Monitoring assays will support the discussion and highlight the versatility of the technology to cope with small molecules as well as large biomolecules.
TUESDAY 28 MAY 2024

IFCC SYMPOSIUM 3

09:00-11:00 ROOM E
THE POTENTIAL OF SINGLE CELL AND SPATIAL BIOLOGY IN THE EVOLUTION OF CLINICAL MEDICINE
Chairs: Andrew South, Paolo Fortina

The potential of single cell and spatial biology for clinical medicine, Paolo Fortina
Using single-cell RNA-sequencing to interrogate biologic drug response in psoriasis, Raymond Cho
Determining the mechanism of action of cancer therapeutics through single cell profiling, Andrew South
Understanding chronic wounds and wound healing using single cell profiling, Ignacia Fuentes

Credits: 2 CPECS®

SYMPOSIUM 4

09:00-11:00 ROOM A
THE ROLE OF LABORATORY MEDICINE IN DIRECT-TO-CONSUMER TESTING (DTCT)
Chairs: Sverre Sandberg, Matthias Orth

What is Direct To Consumer Testing, DTCT and is it compatible with the “choose wisely” campaign? Sverre Sandberg
The variety and range of direct-to-consumer testing, Patti Shih
We must speak up – what is the role of laboratory medicine in DTCT?, Matthias Orth
How to compare point-of-care testing results with hospital laboratory results: recommendations for primary healthcare laboratories, Anne Stavelin
Dutch Multicenter Study: Point-of-Care Test for CT Lesion Prediction in Mild Traumatic Brain Injury using GFAP and UCH-L1, Walid Chayoua

Credits: 2 CPECS®

SSCC SYMPOSIUM 1

09:00-11:00 ROOM B
INBORN ERRORS OF METABOLISM IN SAUDI ARABIA
Chairs: Ali Alothaim, Khalid Al Harbi

Novel inborn errors of metabolism discovery in Saudi Arabia, Majid Alfaadhel
Landscape of Mitochondrial disorders in Saudi Arabia, Naif Almontashiri
Overview of Newborn screening program in Saudi Arabia, Fuad Almutairi
Integrates genomic and Metabolomics technologies to unravel the diagnostic odyssey in rare diseases, Malak Alghamdi

Credits: 2 CPECS®

SYMPOSIUM 5

09:00-11:00 ROOM C
MACHINE LEARNING AND CLINICAL DECISION SUPPORT: TECHNOLOGIES THAT GENUINELY MAKE PEOPLE’S LIFE BETTER
Chairs: Hernán Fares Taie, Waleed Al Tamimi

Clinical decision support and Machine Learning: Improving medical decisions and enhancing the value of the clinical laboratory in healthcare, Hernán Fares Taie
Navigating Through Current ML Applications in Clinical Labs: From Preanalytical to Post-analytical Phases, Deniz İlhan Topcu
Machine Learning in healthcare: Current applications and future perspectives, Stephen Master
Artificial intelligence (AI)-driven clinical decision support to predict urine culture outcome, Lieselot Dedeene
Tackling the implementation hurdle: user-centric validation of a machine-learning decision support tool for the screening of mild bleeding disorders, Henning Nilius

Credits: 2 CPECS®
UAE SYMPOSIUM 1

09:00-11:00 ROOM ABU DHABI B
METABOLIC AND NONCOMMUNICABLE DISEASES
Chairs: Fayha Salah Ahmed, Abdelhalim Chachou

The burden of Non-alcoholic fatty liver disease: screening, diagnosis and management, Fayha Salah Ahmed
Diabetes in UAE, Riad Bayoumi
Markers of Alzheimer and neurological disorders, Laila AbdelWareth

Credits: 2 CPECS®

APFCB SESSION

09:00-11:00 ROOM D
CLINICAL DECISION SUPPORT
Chairs: Kay Weng Choy, Tze Ping Loh

Clinical decision support in clinical practice: a systematic review, Adriana Esho
Electronic clinical decision support for pathology requesting, Ken Sikaris
Considerations for result interpretation clinical decision support, Wei Cui

Credits: 2 CPECS®

UAEGA SESSION

STEM CELLS & REGENERATIVE MEDICINE
Chairs: Sfoug AlShammary, Yahya Kiwan, Fatima Jamali

09:15 - 09:30 Development of myocardial regenerative medicine for severe heart failure
Yoshiki Sawa

09:30 - 09:45 Corneal stem cell therapies: from lab to clinic
Sujjad Ahmad

09:45 - 10:00 Towards a better Understanding of Diabetes-Associated Gene Function through iPSC-Derived Islet Organoids
Essam Abdelalim

Apolipoproteins Have a Major Role in Cellular Tumor Dormancy in Triple Negative Breast Cancer: In-silico Study
Shimaa Elshenawy

Credits: 1 CPECS®

ADVANCING CANCER CARE
Chairs: Burhan Fakhruij, Thomas Adrian, Mahmood Yaseen Hachim Al Mashhadani

Towards eliminating minimal residual disease in ovarian cancer to prevent recurrence
Ahmed Ashour Ahmed

Al in Cancer: Pathology Applications
Aaron Han

EpiGenetics and Cancer
Ali Hamiche

Plasminogen Activator Inhibitor 1: Bridging Bench and Clinic in Cancer Research
Khalid Bajou

Credits: 1 CPECS®
Fowzan S Alkuraya is a Professor of Human Genetics at Alfaisal University and the Chairman of the Department of Translational Genomics at King Faisal Specialist Hospital and Research Center. He joined medical school (King Saud University) before turning 15 and graduated first in his class with first class honors. He did his pediatric residency at Georgetown University Hospital, followed by a fellowship in clinical genetics and another in molecular genetics at Harvard Medical School. He also did a postdoctoral research fellowship in the area of developmental genetics in the lab of Prof. Richard Maas at Harvard Medical School. He returned to his native Saudi Arabia to establish the Developmental Genetics Lab, which later evolved into the Center for Genomic Medicine at KFSHRC. He is an authority in the area of Mendelian genetics with more than 520 published manuscripts that describe his lab’s discovery of hundreds of novel disease genes in humans as well as many other seminal contributions to the field of human genetics as featured in profiles published by The Lancet and Science. He is a frequently invited speaker at local, regional and international conferences, on the editorial board of prominent human genetics journals, and the recipient of numerous prestigious awards including William King Bowes Award in Medical Genetics (first non-US based winner), King Salman Award for Disability Research and Curt Stern Award (first non-US based winner).
IFCC SYMPOSIUM 4

14:30-16:30   ROOM E

ON THE WAY TO CARDIOVASCULAR PRECISION DIAGNOSTICS

Chairs: Tony Badrick, Patrick Bossuyt

Urgent need for Cardiovascular Precision Diagnostics to address Residual Cardiovascular Risk. Christa M. Cobbaert

Establishing an SI-traceable Reference Measurement System for 7 Serum Apolipoproteins. Renee Ruhaak

Evaluating the Clinical Effectiveness of Cardiovascular Precision Diagnostics. Patrick Bossuyt

Demonstrating the clinical value of a multiplexed serum Apolipoprotein Panel in the Odyssey Outcome Study. Esther Reijnders

Credits: 2 CPECS®

SYMPOSIUM 6

14:30-16:30   ROOM ABU DHABI B

DIGITAL COMPETENCE AND ARTIFICIAL INTELLIGENCE IN LABORATORY MEDICINE

Chairs: Damien Gruson, Santiago Fares Taie

Embracing the Digital Frontier: Unveiling Unmet Needs in Laboratory Medicine’s AI Journey. Andrea Padoan

Revolutionizing Diagnostics: The Clinical Value of Artificial Intelligence in Laboratory Medicine. Damien Gruson

Efficiency Amplified: Unleashing Operational Benefits through Digital Competence and AI in Laboratory Medicine. Shaikha Almazrouei

Harnessing GPT-4 turbo for intelligent laboratory test recommendations: a step forward in next-generation clinical decision support. Ahmed Zayed

Leveraging Machine Learning to Improve Current Diagnostic Algorithms and Laboratory Stewardship. He Sarina Yang

Credits: 2 CPECS®
Corporate workshops

Lunch Workshop 8
13.00 - 14.00  ROOM B

Managing the blood sampling volumes: why, who and how?

CHAIR: Ana-Maria Šimundić (HR)

SPEAKER 1: Mario Plebani (IT)

SPEAKER 2: Álvaro González (SP)

PROGRAMME:
13.00/13.25 - Speaker Mario Plebani (IT)
Title: The role of laboratory in managing the blood sampling volumes
13.25/13.50 - Speaker Álvaro González (SP)
Title: Capillary blood sampling – do’s and don’ts
13.50/14.00 - Discussion and Q&A

Learning Objectives:
• To understand which processes lead to excessive and unnecessary blood loss in a patient
• To understand the impact and ethical issues of excessive and unnecessary blood loss
• To be able to identify measures which laboratories may apply to mitigate the unnecessary blood loss
• To understand the difference between capillary and venous blood sample
• To identify possible sources of bias associated with capillary blood collection and how to mitigate these risks

Educational Workshop 9
14.30 - 17.00  ROOM A

Updates on Standardization and Harmonization in Immunoassays

CHAIR 1: Dr. Pilar Fernandez-Calle

SPEAKER 1: Prof. Mario Plebani

SPEAKER 2: Prof. Tomas Zima

SPEAKER 3: Prof. Waleed Tamimi

SPEAKER 4: Prof. Andrey Ivanov

CHAIR 2: Dr. Eduardo Freggiaro

SPEAKER 5: Prof. Etienne Cavalier

SPEAKER 6: Dr. Carlos Garces

SPEAKER 7: Dr. Andrei Komarov

PROGRAMME:
SESSION 1 - 1430-1530
Chair - Dr. Pilar Fernandez-Calle

14:30-14:50 Standardization and Harmonization in Immunoassays: Quality and Comparability Are Needed - Prof. Mario Plebani
14:50-15:10 Tumor Markers Focused on Gastric Area - Prof. Tomas Zima
15:10-15:30 Evaluation of PIVKA II Assay in Patients with Liver Diseases - Prof. Waleed Tamimi
15:30-15:50 Fundamental Scientific Research is a Source of New Opportunities for Laboratory Medicine - Prof. Andrey Ivanov

SESSION TWO 15:50-17:00
Chair - Dr. Eduardo Freggiaro

15:50-16:10 Update on 25-OH Vitamin D Measurement and Metabolites - Prof. Etienne Cavalier
16:10-16:30 ESG for Medical Laboratories. How to Implement from Theory to Practice - Dr. Carlos Garces
16:30-16:50 Ways of Automising Laboratory Performance in the Context of Robotechnics’ Development - Dr. Andrei Komarov

Learning Objectives:
• To understand the increasing importance of data comparability in laboratory medicine
• To understand the differences between standardization and harmonization in laboratory medicine
• To understand differences between clinical chemistry measurands and serology/immunoassay
• To understand the further steps in standardization and harmonization in the total testing cycle
• Understand methods to measure tumor markers
• Interpret concentrations of tumor markers in various gastric disorders
• To know the background and clinical applications of PIVKA-II
• Briefly know the evaluation and comparison results of different PIVKA-II assays
• Understand the different metabolite pathways of vitamin D
• Interpret vitamin D concentrations in different clinical contexts

New Perspectives for the Utility of Big Data Analysis to Derive Reference Intervals Using Indirect Methodology

CHAIR: Dr. Jakob Zierk

SPEAKER 1: Prof. Anwar Borai

SPEAKER 2: Prof. Khosrow Adeli

SPEAKER 3: Prof. Kiyoshi Ichihara

PROGRAMME:
Why Should We Establish Reference Intervals For Each Population? Saudi Population Study as An Example (20 min.) - Prof. Anwar Borai
Big Data Analytics to Harmonize Reference Intervals Across Populations and Analytical Platforms (20 min.) - Prof. Khosrow Adeli
"Critical assessments of reference intervals derived indirectly from laboratory database" (20 min.) - Prof. Kiyoshi Ichihara

Learning Objectives:
• To show how clinical decisions can be affected by the obtained reference intervals (RIs) using the established RIs on Saudi population as an example.
• Define application of big data analytics to determination of indirect RIs and to achieve harmonization across clinical laboratories.
• To show different schemes of data-cleaning for indirectly derived RIs and validate their accuracy in comparison to RIs obtained by direct method.

Managing the blood sampling volumes: why, who and how?

CHAIR: Ana-Maria Šimundić (HR)

SPEAKER 1: Mario Plebani (IT)

SPEAKER 2: Álvaro González (SP)

PROGRAMME:
13.00/13.25 - Speaker Mario Plebani (IT)
Title: The role of laboratory in managing the blood sampling volumes
13.25/13.50 - Speaker Álvaro González (SP)
Title: Capillary blood sampling – do’s and don’ts
13.50/14.00 - Discussion and Q&A

Learning Objectives:
• To understand which processes lead to excessive and unnecessary blood loss in a patient
• To understand the impact and ethical issues of excessive and unnecessary blood loss
• To be able to identify measures which laboratories may apply to mitigate the unnecessary blood loss
• To understand the difference between capillary and venous blood sample
• To identify possible sources of bias associated with capillary blood collection and how to mitigate these risks

Educational Workshop 9
14.30 - 17.00  ROOM A

Updates on Standardization and Harmonization in Immunoassays

CHAIR 1: Dr. Pilar Fernandez-Calle

SPEAKER 1: Prof. Mario Plebani

SPEAKER 2: Prof. Tomas Zima

SPEAKER 3: Prof. Waleed Tamimi

SPEAKER 4: Prof. Andrey Ivanov

CHAIR 2: Dr. Eduardo Freggiaro

SPEAKER 5: Prof. Etienne Cavalier

SPEAKER 6: Dr. Carlos Garces

SPEAKER 7: Dr. Andrei Komarov

PROGRAMME:
SESSION 1 - 1430-1530
Chair - Dr. Pilar Fernandez-Calle

14:30-14:50 Standardization and Harmonization in Immunoassays: Quality and Comparability Are Needed - Prof. Mario Plebani
14:50-15:10 Tumor Markers Focused on Gastric Area - Prof. Tomas Zima
15:10-15:30 Evaluation of PIVKA II Assay in Patients with Liver Diseases - Prof. Waleed Tamimi
15:30-15:50 Fundamental Scientific Research is a Source of New Opportunities for Laboratory Medicine - Prof. Andrey Ivanov

SESSION TWO 15:50-17:00
Chair - Dr. Eduardo Freggiaro

15:50-16:10 Update on 25-OH Vitamin D Measurement and Metabolites - Prof. Etienne Cavalier
16:10-16:30 ESG for Medical Laboratories. How to Implement from Theory to Practice - Dr. Carlos Garces
16:30-16:50 Ways of Automising Laboratory Performance in the Context of Robotechnics’ Development - Dr. Andrei Komarov

Learning Objectives:
• To understand the increasing importance of data comparability in laboratory medicine
• To understand the differences between standardization and harmonization in laboratory medicine
• To understand differences between clinical chemistry measurands and serology/immunoassay
• To understand the further steps in standardization and harmonization in the total testing cycle
• Understand methods to measure tumor markers
• Interpret concentrations of tumor markers in various gastric disorders
• To know the background and clinical applications of PIVKA-II
• Briefly know the evaluation and comparison results of different PIVKA-II assays
• Understand the different metabolite pathways of vitamin D
• Interpret vitamin D concentrations in different clinical contexts
Educational Workshop 11
14:30 - 15:30 ROOM D
Cardiovascular Disease: From Laboratory Diagnosis to Challenges

CHAIR: Prof Tomris Ozben
SPEAKER 1: Prof. Sergio Bernardini
SPEAKER 2: Dr. Fadwa Said Abdelazim

PROGRAMME:
14:30-14:35 Welcome and Introduction - Tomris Ozben
14:35-14:55 Laboratory Test for Cardiovascular Disease - Fadwa Said Abdelazim
14:55-15:25 Cardiovascular risk stratification: a fundamental challenge for laboratory medicine - Sergio Bernardini
15:25-15:30 Discussion

Learning Objectives:
• Analyze the existing practices of laboratory medicine in CVD treatment, including the challenges and prospects involved.
• Understand the significance of the Hs-cTnI test, when paired with clinical and diagnostic findings, in determining the risk of future cardiac episodes in a population perceived as healthy.
• Understand how addition of hs-cTnI into risk assessment algorithms can support appropriate management and treatment.

Educational Workshop 12
14:30 - 15:30 ROOM B
Fecal Calprotectin: A Biomarker for Gastrointestinal Inflammation in IBD - Clinical Insights and Efficient Laboratory Workflow

CHAIR: Christian-Benedikt Gerhold, PhD
SPEAKER 1: Alexander Ohmann, PhD
SPEAKER 2: Prof. Jordi Guardiola
SPEAKER 3: Mrs Rouba Trad

PROGRAMME:
14:30 Calprotectin: Insights into biological function & biochemical analysis – Alexander Ohmann
14:50 Clinical value of calprotectin in the diagnosis and management of patients suffering from IBD – Prof. Jordi Guardiola
15:10 Fecal calprotectin testing in routine lab work: the experience from a reference center - Rouba Trad
15:25 Q&A session

Learning Objectives:
• Gain an understanding of the interesting and complex biochemistry of calprotectin and its significance as an important player in the innate immune system.
• Learn about the clinical importance of calprotectin levels and how it influences IBD patient management.
• Learn how to implement fecal calprotectin testing into automated and optimized laboratory workflow and how to overcome analytical and pre-analytical challenges.

Visit store.randox.com
to buy directly from Randox today
randox.com
marketing@randox.com
Product availability may vary from country to country. Some products may be for Research use Only.
For more information on product application and availability, please contact your local Randox representative.
SYMPOSIUM 5

09:00-11:00 ROOM E
BIOMARKERS FOR NEURODEGENERATIVE DISEASES - IDENTIFICATION, STANDARDIZATION OF PREANALYTICAL AND ANALYTICAL PROCEDURES AND CLINICAL VALIDATION

Chairs: Hans Frykman, Kaj Blennow

The different clinical types of dementia – epidemiology. Robin Hsiung
Metrological standardization of AD biomarkers - current status future perspectives. Henrik Zetterberg
Identifying clinically useful biomarkers in neurodegenerative diseases - moving from CSF to blood. Kaj Blennow
Biomarker panels: analytical and clinical validation against clinically relevant reference standards. Hans Frykman

SYMPOSIUM 7

09:00-11:00 ROOM A
MEETING THE CHALLENGE OF DEMONSTRATING VALUE IN LABORATORY MEDICINE

Chairs: Andrew St John, Phillip Monaghan

The challenges of delivering value through better test implementation. Andrew St John
How we harnessed laboratory data to improve health and economic outcomes. David G. Grenache
Impact of a cyber attack on laboratory operations in a university hospital: immediate response and patient security. Sana Yaacoub
Le Mans Protocol – evidence-based approach to proof your choice of production concept. Jean-Philippe Galhaud, Daria Dimitrova

SYMPOSIUM 8

09:00-11:00 ROOM B
HOW TO IMPROVE ACCESS TO LAB TESTING IN MIDDLE & LOW INCOME COUNTRIES?

Chairs: Mario Plebani, Michael Wilson

The Lancet Commission on Diagnostics. Michael Wilson
A Global Diagnostics Alliance. Mikashmi Kohli
The WHO model list of essential in vitro diagnostics and its role in improving access to lab testing in LMICs. Ana Aceves Capri
Can lipid mediators be useful biomarkers in schizophrenia? Ahlem Ben Messaoud

AFCB SYMPOSIUM 2

09:00-11:00 ROOM C
EPIDEMIC AND PANDEMIC INFECTIOUS IN ARABIC REGIONS

Chairs: Abderrazek Hedhili, Hiba Badi Eldin Khalil

Earthquakes, wars, and emerging infectious disease. Christian Haddad
Evolution of the epidemiology of viral diseases in relation to migratory movements in the Arab Maghreb countries. Abdelhalim Trabelsi
Prevalence and incidence Rate of infectious diseases in the Middle east and North Africa: Management of such diseases in low-income countries. Ghassan Shannan
Viral transmission from animal to humans (zoonosis) in Middle East Challenges and risks. Robin Abu Ghazaleh

Credits: 2 CPECs®
SYMPOSIUM 9

09:00-11:00 ROOM D
HEALTHCARE DELIVERY IN THE 21 CENTURY AND THE ROLE OF THE CLINICAL LABORATORY
Chairs: Nader Rifai, Nashat Nafouri

Implementation of Emerging Technologies, Ronda Greaves
Sustainability and Environmental Impact of the Clinical Laboratory, Ian Young
The Role of the Clinical Laboratory in Supporting Equity in the Delivery of Healthcare, Christina Pierre
A Green Laboratory Approach to Medical Sample Transportation between two Medical Laboratories: Assessing the Environmental Impact of Drone, Combustion Car, and Electric Car Transportation of Medical Samples, Noel Rouven Stierlin
Green laboratory medicine in Africa: what is the contribution to environmental toxicity and how prepared is the continent for sustainable laboratory medicine? John Anetor

Credits: 2 CPECS®

Nader Rifai (USA)
Nashat Nafouri (Saudi Arabia)
Ronda Greaves (Australia)
Ian Young (UK)
Christina Pierre (USA)
Noel Rouven Stierlin (Switzerland)
John Anetor (Nigeria)

COLABIOCLI SESSION

09:00-11:00 ROOM ABU DHABI B
EMERGING AND RE-EMERGING DISEASES IN LATIN AMERICA, A VIEW FROM PUBLIC HEALTH
Chairs: Maria Elizabeth Menezes, Moises Ramos Solano

Current Molecular Diagnosis of Dengue, Zika and Chikungunya in the Region of the Americas, Maria Elizabeth Menezes
Molecular and Epidemiological Aspects of Dengue Infection, Moises Ramos Solano
Advances in the study of innate immunity against Mycobacterium tuberculosis, Luisa Maria Nieto Ramirez
Zika a Virus that changed the History of a Generation, Marcelo Mancato

Credits: 2 CPECS®

Maria Elizabeth Menezes (Brazil)
Moises Ramos Solano (Mexico)
Luisa Maria Nieto Ramirez (Colombia)
Marcelo Mancato (Colombia)

09:00 - 09:15 ROOM F
Opening Message
Maryam Matar (UAE)

UAEGDA SESSION

GENOMICS OF RARE DISEASES I
Chairs: Bassam Ali, Maryam AlShehhi, Shaikha Almazrouei

09:15 - 09:40 Unraveling common dyslipidemia in a population through genetic screening
Fahad Mahmood Al Zadjali

09:40 - 10:00 Genetics of Pediatric Cardiomyopathy: New Findings and Challenges, Alireza Haghighi

10:00 - 10:15 Deciphering the Genetic Landscape of ADPKD: Paving the Way for Novel Therapeutic Targets, Hamad Ali Yaseen

10:15 - 10:30 Newly identified Syndromes with novel phenotypes in Omani patients, Musallam Al Araimi

10:30 - 10:45 Promoting Rare Diseases Research in China: Challenges and Solutions, Boya Yu

10:45 - 11:00 Deconstructing rare diseases with functional genomics - a Middle Eastern adventure
Luis Saraiva

Credits: 1.5 CPECS®

Bassam Ali (UAE)
Maryam AlShehhi (UAE)
Shaikha Almazrouei (UAE)
Fahad Mahmood Al Zadjali (Oman)
Alireza Haghighi (USA)
Hamad Ali Yaseen (Kuwait)
Musallam Al Araimi (Oman)
Boya Yu (China)
Luis Saraiva (Qatar)

IFCC WORLDLAB 2024
Prof Liesbeth van Rossum, MD PhD, is internist-endocrinologist and professor in the field of obesity and stress hormone research at the Erasmus University Medical Center, Rotterdam, Netherlands. She is co-founder of the Obesity Center CGG, an internationally recognized academic center of expertise for diagnostics of underlying causes of obesity and personalized treatments. Currently, Van Rossum holds various societal and board positions, amongst which European lead of the theme Obesity, Diabetes, Nutrition and Metabolism of the European Society for Endocrinology, member of the European Policy Working Group for obesity, chair of the National Obesity Guideline, and president of the Partnership Overweight Netherlands, an umbrella organization of 20 associations of health care organisations, with an advisory role to the Ministry of Health Welfare on obesity policy. She received multiple international awards and grants for her scientific research, is a frequently invited speaker on scientific congresses, (inter)national media, TEDx, and published with colleague Mariette Boon an international award-winning book “FAT, the secret organ”.

Credits: 1 CPECS®

UAEGDA SESSION

13.00 - 14.00 ROOM F
WORKSHOP GENETICS FOR NON-GENETISTS

Emerging Applications of Next-Generation Sequencing in Disease Biology, Mariam AlEissa
Global Scenario of GC education and training and the possible strategic plans for the MENA region B. R. Lakshmi, Qurratulain Hasan

Credits: 2 CPECS®
UAEGDA SESSION

16.15 - 17.00 ROOM F
GENOMICS OF RARE DISEASES III
Chairs: Hibat Omer, Mariam AlEissa, Noura Almatrooshi

16:15 - 16:35 A Holistic Model Addressing the Needs of Rare Disorders - Case of Duchenne Muscular Dystrophy (DMD). B. R. Lakshmi
16:35 - 17:00 Breaking the $100 Genome Barrier: Our Journey from Bp to Pb, Toby Huang

Credits: 0,5 CPECS®

AFCC SESSION

14:30-16:30 ROOM D
INBORN ERRORS OF METABOLISM IN AFRICA
Chairs: A.B. Okesina, John I. Anetor

Challenges in National Newborn Screening Program in Africa, A.B. Okesina
Prevalence of Inborn Errors of Metabolism in Africa, John I. Anetor
Clinical, Laboratory and Molecular Spectrum of Galactosaemia in Newborns in Africa, R.T. Erasmus
Requirements for the establishment of Newborn Screening Program in Africa, G.T. Aklalu

Credits: 2 CPECS®

SYMPOSIUM 10

14:30-16:30 ROOM B
TOXICOLOGY ENVIRONMENTAL AND HEALTH EFFECTS
Chairs: Abderrazek Hedhili, Ahmad Al Asmari

Use of Per- and polyfluoroalkyl substances (PFASs) in medical technologies, what are the challenges with finding alternatives, how these technologies containing PFAS are handled at the end of life and how risks are managed, Aldo Tomasi
Exposure and Health Effects of Perfluoroalkyl Substances (PFAS): Insights from Population Surveys and Risk Assessment, Nolwenn Noisel
The evolution of human biomonitoring and its impact on clinical laboratory medicine, David Kinniburgh

Credits: 2 CPECS®

NAFCC SESSION

14:30-16:30 ROOM E
LABORATORY MEDICINE ADVANCING GLOBAL HEALTH ACROSS THE LIFESPAN
Chairs: Octavia M Peck Palmer, Paul M. Yip

Pediatric health: Vitamin and Trace element testing, Kamisha Johnson-Davis
New chance at life: Infectious disease testing, Allison A Venner
Maternal-fetal health: Early detection of pre-eclampsia, Paul M. Yip
Medically underserved populations: Delivering evidence-based care via point of care testing, Octavia M Peck Palmer

Credits: 2 CPECS®
Learning Objectives:

- Know the trends in diagnostics
- Understand Intelligent Laboratory and iXLAB
- Understand various detection techniques and their applications in the future
- To know the situation of blood donor screening and the challenges confronting
- To understand the methods and strategies in blood donor screening
- To know the importance and challenges of establishing the reference interval.
- To understand what to do for reference interval in the future
- Review assay methodology, quality control and assurance and gain insights into troubleshooting potential quality issues in reproductive hormone chemiluminescence assays.
- Interpretation of reproductive hormone assays in different scenarios, such as infertility assessments, hormonal disorders, and monitoring hormone replacement therapies.
- Review and compare different methods for endocrine function.

Transformation of patient care with tailored laboratory solutions

The demand on labs is greater than ever, bringing with it the need to operate more efficiently while maintaining precision. Join us to discover how QuidelOrtho’s comprehensive range of solutions addresses the challenges of increasing workloads and stretched personnel by streamlining routine tasks and saving valuable hours.

Informatics that power your lab: High-quality results, faster

Vitros® Results Management allows labs to easily standardize configurations, build auto verification rules, view integrated quality control (QC) and moving averages, allowing you to focus on what really matters – your patients' lives.

Elevating precision medicine with advanced point-of-care and molecular diagnostics

Transformative potential of point-of-care testing in key clinical scenarios with an emphasis on improving patient care and fostering diagnostic stewardship programs.

Join us at IFCC WorldLab 2024

26-30 May | Booth #850
Dubai World Trade Centre

Els Melis
Senior Marketing Manager Clinical Labs, QuidelOrtho

Khosrow R. Shotorbani MBA, MT (ASCP)
President, Executive Director Project Santa Fe Foundation. Founder, CEO Lab 2.0 - Strategic Services, LLC

Corporate Workshops

Educational Workshop 17
14:30 - 17:00 | ROOM A
Looking beyond the Future of Laboratory Medicine

CHAIR 1: Prof. Praveen Sharma
SPEAKER 1: Prof. Maurizio Ferrari
SPEAKER 2: Prof. Issam Frigaa
SPEAKER 3: Dr. Ali Bayoumi
SPEAKER 4: Prof. Aaron Han

CHAIR 2: Prof. Vincent Sapin
SPEAKER 5: Prof. Tahir Pillay
SPEAKER 6: Dr. B. K. T. P. Dayanath
SPEAKER 7: Dr. Dheepa Manoharan

SESSION 1 - 14:30-15:50
Moderator - Prof. Praveen Sharma
14:30-14:50 How to Imagine the Future of Laboratory Medicine - Prof. Maurizio Ferrari
14:50-15:10 Strategies and New Challenges in Blood Donor Screening - Prof. Issam Frigaa
15:10-15:30 Establishing Reliable Reference Intervals: a Crucial Step in Accurate Diagnosis and Treatment - Dr. Ali Bayoumi
15:30-15:50 Laboratory Quality Management and CAP Accreditation - Prof. Aaron Han

SESSION 2 - 15:50-17:00
Moderator – Prof. Vincent Sapin
15:50-16:10 Reproductive Hormone Assays Using Chemiluminescence - Prof. Tahir Pillay
16:10-16:30 Dynamic & Invasive Endocrine Function Tests - Dr. B. K. T. P. Dayanath
16:30-16:50 Quality in Chemistry - Dr. Dheepa Manoharan

Learning Objectives:

- Know the trends in diagnostics
- Understand Intelligent Laboratory and iXLAB
- Understand various detection techniques and their applications in the future
- To know the situation of blood donor screening and the challenges confronting
- To understand the methods and strategies in blood donor screening
- To know the importance and challenges of establishing the reference interval.
- To understand what to do for reference interval in the future
- Review assay methodology, quality control and assurance and gain insights into troubleshooting potential quality issues in reproductive hormone chemiluminescence assays.
- Interpretation of reproductive hormone assays in different scenarios, such as infertility assessments, hormonal disorders, and monitoring hormone replacement therapies.
- Review and compare different methods for endocrine function.

Transforming patient care with tailored laboratory solutions

The demand on labs is greater than ever, bringing with it the need to operate more efficiently while maintaining precision. Join us to discover how QuidelOrtho’s comprehensive range of solutions addresses the challenges of increasing workloads and stretched personnel by streamlining routine tasks and saving valuable hours.

Informatics that power your lab: High-quality results, faster

Vitros® Results Management allows labs to easily standardize configurations, build auto verification rules, view integrated quality control (QC) and moving averages, allowing you to focus on what really matters – your patients’ lives.

Elevating precision medicine with advanced point-of-care and molecular diagnostics

Transformative potential of point-of-care testing in key clinical scenarios with an emphasis on improving patient care and fostering diagnostic stewardship programs.

Join us at IFCC WorldLab 2024

26-30 May | Booth #850
Dubai World Trade Centre
THURSDAY 30 MAY 2024

SYMPOSIUM 11

09:00-11:00  ROOM E
CIRCULATING CANCER BIOMARKERS: QUO VADIS?
Chairs: Ron HN van Schaik, Dobrin Svinarov

Liquid biopsy / cell-free DNA analysis: too hot to handle, or right up our alley? Ron HN van Schaik
Liquid biopsy: from discovery to clinical implementation, Simon Joosse
Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immune therapy in patients with NSCLC, Marzia del Re
Improving endpoint digital PCR in multiplexing capacity and specificity for multigene-associate disease detection, Dongdong Liu

Credits: 2 CPECS®

SYMPOSIUM 12

09:00-11:00  ROOM A
PREVENTING KIDNEY DISEASE USING ADVANCED URINE SCREENING AND KIDNEY DAMAGE MARKERS
Chairs: Joris Delanghe, Osama Najjar

Update to laboratory assessment of kidney diseases, Joris Delanghe
Preventing diabetic nephropathy, follow-up with laboratory markers, Marc De Buyzere
Urinary particle analysis in detection of kidney diseases, Rosanna Falbo
Raman spectroscopic analysis of urine combined with machine learning identifies life-threatening inborn errors of metabolism, Jing Cao
Interferences in non-immunological albumin assays by carbamylated albumin, Hans Günther Wühl

Credits: 2 CPECS®

SYMPOSIUM 13

09:00-11:00  ROOM C
PERFORMANCE SPECIFICATIONS OF MEDICAL TESTS BASED ON CLINICAL OUTCOME STUDIES
Chairs: Andrea Rita Horvath, Mohammed Habbab

Outcome-based analytical performance specifications - current status and future directions, Andrea Rita Horvath
Testing related outcomes and analytical performance - the linked evidence approach, Patrick Bossuyt
A practical approach to determining blood ketone performance specifications, Eric Kilpatrick
Why most diagnostic studies overestimate test performance: evidence from a large-scale meta-analysis, Michael Nagler
Implementation and evaluation of hyper-automated newborn bloodspot screening for SCID and SMA in Victoria, Australia, Nazha Mawad

Credits: 2 CPECS®

SSCC SYMPOSIUM 2

09:00-11:00  ROOM B
DYSGLYCEMIA - NOVEL BIOMARKERS FOR DIAGNOSIS AND MONITORING PROGNOSIS
Chairs: Suhad Bahijri, Manel Chaabane

Epidemiology of Diabetes in the Arabian Gulf Countries: Challenges and Opportunities, Yousef Al Saleh
Use Of Glycated Products In Diagnosis, Nafila Al Ryami
Use of 1-hour glucose challenge test in diagnosis and predicting future complications, Jaakko Tuomilehto
Novel Biomarkers to improve diagnosis and monitor prognosis, Suhad Bahijri

Credits: 2 CPECS®
SYMPOSIUM 14

09:00-11:00 ROOM D

UTILIZATION MANAGEMENT AND SUCCESSFUL APPROACHES TO CHANGE AND IMPROVE TEST REQUESTING

Chairs: Mario Plebani, Waleed Al Omaim

Utilization management and appropriateness in clinical laboratory: state-of-the-art, Mario Plebani
How to deal with inappropriate laboratory retesting? Ivana Lapic
The noble art of leaving out, Prabath Nanayakkara
Monitoring magnesium status in the pediatric liver transplant: total or ionized? Estefani Martinez Chávez
Comparison of non-invasive testing strategies by costs and referral rates in veteran population with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Artem T. Boltyenkov

Credits: 2 CPECS®

UAE SYMPOSIUM 2

09:00-11:00 ROOM ABU DHABI B

AI & MACHINE LEARNING APPLICATIONS IN LABORATORY MEDICINE

Chairs: Laila AbdelWareth, Ola Elgaddar

Case study of machine learning and AI application in pathology, Ayub Nahal
AI and Decision support systems, Hady Elhaddary Dubai
Intraoperative Mass Spectrometry: Recent updates and Challenges to Implementation, Shereen Hassan Atef
Medical Laboratories between shrinking workforce and Artificial Intelligence, Ola Elgaddar

Credits: 2 CPECS®

UAEGDA SESSION

GLOBAL HEALTH AI: UNITING NATIONS FOR GENOMIC INSIGHTS AND DATA GOVERNANCE

Chairs: Mazin Gadir, Fady Hannah-Shmouni, Philippe Gerwill

09:15 - 09:30 From Data to Action: AI-powered Personalized Medicine and Global Health Equity
Noor AlSaadoun
09:30 - 09:45 Will Artificial Intelligence deliver Genomic Medicine? Review of applications of artificial intelligence in genomic medicine
Mark Bartlett
09:45 - 10:00 The Automation of Clinical Genetic Data through Implementation of ACMG guidelines
Mariam Eldesouky
10:00 - 10:15 Beyond Borders, Beyond Bias: Can XR Revolutionize Healthcare Equity?
Sana Farid
10:15 - 10:30 PreciousGPT: Multimodal multomics multi-species, multi-tissue multitasking transformers for aging research and drug discovery
Alex Zhavoronkov

Credits: 1,5 CPECS®

UAEGDA SESSION

PANEL DISCUSSION - GENOMICS IN THE METAVERSE

Chairs: Philippe Gerwill, Noor AlSaadoun

10:45 - 11:30 Panel discussion
Muhammed Fafis, Khulood AlSayegh, Alex Zhavoronkov, Sonal Ahuja, Sana Farid

Credits: 0,5 CPECS®
Carl Wittwer, MD, PhD is Professor Emeritus of Pathology at the University of Utah. With more than 200 articles focusing on technique and instrument development in molecular diagnostics, he developed rapid PCR (15 min) in the 1990s and was the primary inventor of the LightCycler® system, with over 10,000 units placed worldwide by Roche. Carl holds over 40 US patents and their foreign equivalents. He introduced SYBR Green, hybridization probes, and melting analysis to real-time PCR and continues to develop extreme PCR (< 1 min) and high-speed DNA melting (<5 s). Carl co-founded BioFire Diagnostics and served as Chairman of the Board from 2012 until its acquisition by bioMérieux in 2014, most notable for the FilmArray syndromic diagnostic platform with over 20,000 placements worldwide. He is an Associate Editor of Clinical Chemistry and chair of the Scientific Advisory Board of CoDiagnostics. Much of his work can be found at www.dna-utah.org.

**Credits:** 1 CPECS®
IFCC WORLDLAB 2024

The Closed Meetings will be held at Conrad Hotel

25 Saturday May 2024
09:00-17:00 IFCC SD-EC – Chair: C. Cobbaert
09:00-17:00 IFCC CPD-EC – Chair: T. Pillay

26 Sunday May 2024
08:30-12:30 IFCC EM-EC – Chair: N. Rihai
08:30-12:30 IFCC CPD-EC – Chair: T. Pillay
08:30-12:30 IFCC TF-GLO – Chairs: E. Amann, G. Meng
08:30-16:00 IFCC Young Scientists Forum
08:30-16:30 IFCC C-ETPLM – Chair: L. Kyrilakopoulou
09:00-12:30 IFCC SD-EC – Chair: C. Cobbaert
09:00-13:00 IFCC TF-GRID – Chair: J. Zierk
09:00-13:00 IFCC TF-OSLM – Chair: Z. Zhao
09:00-16:00 IFCC C-NPU – Chair: Y.B. Lee
13:00-16:00 IFCC Council
13:00-17:00 IFCC C-KD – Chair: J. El Khouri
13:30-17:30 IFCC C-RIDL – Chair: T. Streichert

27 Monday May 2024
08:30-12:30 IFCC WG-FC – Chair: C. Lambert
08:30-15:30 IFCC C-PR – Chair: MdC Pasquel
08:30-17:00 IFCC ETD-EC – Chair: D. Gruison
08:30-17:00 IFCC C-EUBID/Hbasc
08:30-17:00 Chairs: E. English, C. Siebelder
08:30-17:00 IFCC C-IDC – Chair: D. Topcu
09:00-11:00 IFCC TF-CM – Chair: J.S. Blanchet
09:00-13:00 IFCC C-CC – Chair: F. Lattinen
09:00-13:00 IFCC C-PCT – Chair: A. Khan
09:00-13:00 IFCC C-BM – Chair: E. Cavalier
09:00-13:00 IFCC C-EBLM – Chair: A. Don Wauchope
09:00-13:00 IFCC WG-LEPS – Chair: A. Reibani
11:30-13:30 IFCC Executive Board / Corporate Members
13:30-17:30 IFCC C-CCLM – Chair: P. Sharma
13:30-17:30 IFCC TF-NBS
Chairs: J. Bonham, A. Habib Khan
13:30-17:30 IFCC WGF-ANT – Chair: R. Girardi
14:00-17:30 IFCC TF-LMPG – Chair: T.P. Loh
14:00-17:30 IFCC C-STFT – Chair: K. Van Uytvangerhe
14:00-17:30 AACC EB Members
15:00-18:00 IFCC WG-PCT – Chair: A. Boeuf

28 Tuesday May 2024
08:30-11:30 IFCC WG-EN – Chair: K. Psarra
08:30-13:00 IFCC APFCB EB – Chair: T. Badrick
08:30-13:00 IFCC WG-M – Chair: E. Flux
08:30-13:00 IFCC WG eIFCC
Chairs: HP. Batthoa, K. Vaidyanathan
08:30-13:00 IFCC WG-NB – Chairs: R. Geaves – L. Macka
12:30-16:30 IFCC WG-SCST – Chair: A. South
13:00-17:00 IFCC TF-YS – Chair: S. Fares Taei
13:30-17:30 IFCC C-TLM – Chair: D. Groote-Koska
13:30-17:30 IFCC TF-GEI – Chair: A. Park
14:00-17:30 IFCC WG-AIGD – Chair: SH Yang
14:00-17:30 IFCC C-MHBLM – Chair: J. Nichols

29 Wednesday May 2024
08:30-12:30 IFCC WG-CGM – Chair: G. Freckmann
09:00-13:30 IFCC WG-MEP – Chairs: R. Geaves - TP Loh
13:30-17:30 IFCC TF-GLQ – Chairs: E. Amann, Q. Meng
17:00-18:30 IFCC C-ETPLM – IFCC President: T. Ozben

30 Thursday May 2024
14:00-17:30 IFCC EB Meeting – IFCC President T. Ozben

31 Friday May 2024
14:00-17:30 IFCC EB Meeting – IFCC President T. Ozben
IFCC WORLDLAB 2024

SPEAKERS & CHAIRS

Stavelin Anne, The Norwegian organisation for quality improvement of laboratory examinations (Noklus), Haraldsplass Dianoness Hospital, Bergen, Norway
Sterlin Noel Rouven, Private Universität Liechtenstein / Labormedizinisches Zentrum Dr Risch
Stratton Rachel, UACEGA
Sura Thanachai, Mahidol University, Naikon Pathorn (MU)
Svinarov Dobrin. Head, Clinical Laboratory & Clinical Pharmacology, President, Balkan Clinical Laboratory Federation, Alexander University Hospital, Faculty of Medicine Medical University of Sofia, Bulgaria
Taufeer Alam Mohammad, UAEU
Tomasi Aldo, Scientific Director Technopole of Mirandola and President Clust-ER Health Emilia-Romagna
Topcu Deniz Ilhan, IZMIR CITY HOSPITAL
Tribelsi Abdelhalim, University of Monastir, Faculty of Pharmacy, University Hospital Sahliou Sousse
Tuomilehto Jaakko, University of Helsinki
Urtizberea Jon Andoni, Salpetriere University Hospital
Van Rossum Elisabeth F.C. Erasmus Medical Center Rotterdam
van Schaik Ron HN, Erasmus MC - University Medical Center
Vauzour David, University of East Anglia
Venner Allison, Alberta Precision Labs / University of Calgary
Verna Roberto. World Association of Societies of Pathology and Laboratory Medicine
Wahl Hans Günter, MSB Medical School Berlin, Campus Berlin-Buch
Wilson Michael. Lancet Commission on Diagnostics
Wittwer Carl, University of Utah, USA
WuhreManfred. Leiden University Medical Center
Yaacoub Sana. University of the Holy Spirit Kaslik (USEK), Faculty of Medicine and Medical Sciences, Jounieh, Lebanon
Yang He Sarina. Weil Cornell Medicine
Yaseen Hamad All, Kuwait University
Yip Paul M, Sunnybrook Hospital and University of Toronto
Young Ian. Centre for Public Health, Queen’s University Belfast, UK
Yu Boya. HopeaRare
Zaatnc Alla. The AEON Clinic
Zayed Ahmed. KU Leuven
Zetterberg Henrik, University of Gothenburg
Zhavoronkov Alex. Insilico
Zoubib Mohammed, Alfaisal University, Riyadh, Saudi Arabia

Transform your diagnostic testing with the Optilite® Analyser

The robust and proven analyzer from The Binding Site, bringing you a reliable and optimized solution for special protein testing

- Unique menu with over 50 assays
- Fast and consistent throughput averaging 120 tests/hour
- Global installations > 1500 system supported by technical and scientific experts
- No manual dilutions
- 3 methods for antigen excess detection
- Compact and robust analyser with average MTBF* > 19 months‡

Visit us at Booth 44 to discuss our protein diagnostic solutions

‡ Based on 12 months global data between January 2023 and December 2023
* Mean time between failure

For extraordinary protein diagnostics
**Congress Secretariat**

**MZ EVENTS S.R.L.**  
Via C. Farini 81 - 20159 Milano (Italy)  
Phone: +39 02 66802323  
E-mail: info@dubai2024.org

For information on any specific topic, please refer to the following e-mails:  
General information: info@dubai2024.org  
Abstracts & Posters: posters@dubai2024.org  
Companies: companies@dubai2024.org  
Registrations: registrations@dubai2024.org  
Hotel reservation: ostoyanova@kenes.com

---

### REGISTRATION DESK

The registration desk, located in Concourse 2, is open as follows:

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>26 May 2024</td>
<td>11:00 - 19:00</td>
</tr>
<tr>
<td>27 May 2024</td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>28 May 2024</td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>29 May 2024</td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>30 May 2024</td>
<td>08:30 - 14:00</td>
</tr>
</tbody>
</table>

---

### CONGRESS LANGUAGE

The official language of the congress is English. No simultaneous translation is provided.

---

### NAME BADGE

Participants will print the badge at the kiosks located in the Concourse 2. The QR code and the ID number, received by e-mail after the online pre-registration will be mandatory for the printing. The badge must be worn at all times because only registered participants will be admitted to the scientific sessions.

---

### CONGRESS KIT

The congress kit can be collected at the Bags delivery Desk in the Concourse 2, upon presentation of the name badge.

---

### CERTIFICATE OF ATTENDANCE

All properly registered attendees will receive a certificate of attendance via e-mail, the week after the congress.

---

### CLOAKROOM

No cloakroom is available in the Congress Centre. Delegates are kindly invited to leave suitcases in the hotels.

---

### AUDIOVISUAL CENTRE

The audiovisual centre is located at the Mezzanine Level. Speakers are kindly requested to bring their presentation to the audiovisual centre on a USB drive at least two hours before the presentation is scheduled. Personal laptops cannot be connected to the system.

---

### CONGRESS APP

The App is designed to enrich delegates’, visitors’, and exhibitors’ experience. Search “IFCC WorldLab 2024” in the App Store or Google Play and download.

---

### E-POSTERS

E-posters are available in the Exhibition Area (Hall 7) from Monday to Wednesday.

---

### ABSTRACT PUBLICATIONS

All abstracts are published in a special on-line issue of Clinica Chimica Acta (CCA).

---

### WIRELESS CONNECTION

In the venue there is a complimentary guest WiFi service. Connect to the network “aDWTC Free-WiFi” and enter your details; you will receive a confirmation message.
Full registration and young registration fees include:
- entrance to plenary lectures, symposia, educational workshops, poster area and exhibition
- a free app containing the Scientific Program with the e-posters
- certificate of attendance
- coffee and tea service during morning intermissions
- Opening Ceremony (Sunday, 26 May 2024)
- Closing Ceremony (Thursday, 30 May 2024)

The day registration fee includes, for the day of registration only:
- entrance to plenary lectures, symposia, educational workshops, poster area and exhibition
- a free app containing the Scientific Program with the e-posters
- certificate of attendance
- coffee and tea service during morning intermissions

On-site registration

<table>
<thead>
<tr>
<th>Registration Type</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Registration</td>
<td>€750.00</td>
</tr>
<tr>
<td>Young Registration</td>
<td>€375.00</td>
</tr>
<tr>
<td>Day Registration</td>
<td>€250.00</td>
</tr>
</tbody>
</table>

Delegates can pay registration fees in euros only; cash or credit card (American Express, MasterCard, Visa) accepted.

LIABILITY AND INSURANCE
Registration fees do not include the insurance of participants against personal accidents, sickness and cancellations by any party, theft, loss or damage to personal possessions.

INDUSTRY EXHIBITION
The exhibits of diagnostics companies make up a very important part of the congress. All major international and local clinical-biochemistry and laboratory-medicine companies are represented.

Participants are encouraged to visit the large industry exhibition, which is located in the Hall 7 and open as follows:

- Monday, 27 May       10:00 - 17:30
- Tuesday, 28 May      10:00 - 17:30
- Wednesday, 29 May    10:00 - 17:30

Access to the exhibition area is free of charge and does not require congress registration. However, for security reasons, anyone wishing to visit the exhibition without registering for the congress must report to the Visitors Kiosks or Desks located in the Concourse 2.

COFFEE POINTS
During intermission in the morning, inside the exhibition area, self-service coffee points offer coffee and tea free of charge for all properly registered delegates.

CASH BAR
Many cash bars will be operating inside the DWTC.
Founded in 1995, Snibe is a global leading in-vitro diagnostic solution provider who has focused on the chemiluminescence immunoassay (CLIA) field for more than 28 years and also become the first CLIA manufacturer in China to get FDA-cleared. At present, we have provided customized diagnostic solutions to laboratories in more than 153 countries and regions. Over 30000 units of Snibe’s products have reached worldwide, including global chain labs and hospitals like Synlab, Eurofins, Cerba, Synevo, etc.

Snibe established 4 core R&D centers, including reagent, instrument, magnetic microbead, and reagent raw material to lay a solid foundation for developing the broadest range of CLIA analyzers and a relevant test menu with more than 200 parameters. Under strong technical support, we successfully launched one of the fastest CLIA analyzer in the world - MAGLUMI X8 with a throughput of 600T/H in 2018; In order to meet the demand of mega-laboratories, Snibe announced a strategic partnership with Thermofisher and Hitachi to launch the Total Laboratory Automation solution in 2019; Moreover, to help fight against COVID-19, Snibe successfully developed the 2019-nCoV (SARS-CoV-2) CLIA Kits in 2020, the first of its kind in the world to receive the CE mark.

“Creating value for human health through continuous innovation” is our mission. Snibe’s striving for excellence never ends.

Address and Contact Details:
No. 23, Jinxiu East Road,
Pingshan District 518122 Shenzhen, P. R. China
sales@snibe.com

26th IFCC-EFLM EUROMEDLAB
CONGRESS OF CLINICAL CHEMISTRY
AND LABORATORY MEDICINE

49th ANNUAL MEETING OF THE ROYAL
BELGIAN SOCIETY OF LABORATORY
MEDICINE

FROM 18 TO 22
MAY 2025

VENUE
Brussels Expo
The key to recovery is often a fast, accurate diagnosis, perhaps today more than ever. There have been many new demands placed on laboratories, but there are also new opportunities to help solve some of healthcare’s toughest challenges. Our end-to-end diagnostics solutions including our innovative Alinity family of systems, total laboratory automation and AlinIQ informatics, are used in hospitals and laboratories around the globe. The crucial information from our tests is often the first step in patient care decision making for hundreds of health conditions from heart attacks to blood disorders to infectious disease concerns. Discover how we can collaborate to help you achieve measurably better healthcare performance with our personalized solutions.

Address and Contact Details:
Abbott GmbH
Max-Planck-Ring 2 - 65205 Wiesbaden, Germany
Tel: +496122 580 - wired@abbott.com

As a world leader in in vitro diagnostics, QuidelOrtho develops and manufactures intelligent solutions that transform data into understanding and action for more people in more places every day. By uniting the power of Quidel Corporation and Ortho Clinical Diagnostics, QuidelOrtho offers industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.

Building upon an 80-year legacy of groundbreaking innovation, we continue to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.

At QuidelOrtho, we are transforming the power of diagnostics into a healthier future for all.

Address and Contact Details:
Felindre Meadows, Pencoed
Bridgend. CF35 5PZ
www.quidelortho.com

The Binding Site, a part of Thermo Fisher Scientific
For extraordinary protein diagnostics
Optimizing Multiple Myeloma, immune system disorders, and special protein diagnostics through 35 years of scientific leadership. We provide specialist diagnostic products to clinicians and laboratory professionals worldwide. Our people are dedicated to improving patient lives, delivering innovative medical solutions that improve the diagnosis and management of blood cancers and immune system disorders. Our mission is to enable our customers to make the world healthier, cleaner, and safer.

Address and Contact Details:
8 Calthorpe Road, Edgbaston, Birmingham, B15 1OT
info@bindingsite.com

At Greiner Bio-One, we’re not just a company; we’re a global force in Preanalytics and Diagnostics. Our cutting-edge products are the heartbeat of medical and laboratory innovation, supporting partners from hospitals to biotech giants.

As a Global Top Player, we’re proud to be among the elite in Preanalytics. In the dynamic landscape of the direct market, Greiner Bio-One adeptly tailors its offerings to meet the specific needs of clients. Simultaneously, as an Original Equipment Manufacturer (OEM), we partner in design and production, tailoring our services to meet the unique needs of the life sciences and medical sectors. Discover the Greiner Bio-One difference – where innovation meets precision and direct market expertise.

Our expertise is divided into three dynamic divisions:
• Preanalytics: Revolutionizing specimen collection for both human and animal health.
• BioScience: Advancing cell culture technology, high-throughput screening, and cryopreservation.
• Mediscan: Setting the standard in sterilization.

Founded in 1991, Mindray is a leading global provider of medical devices and solutions. Firmly committed to our mission to “advance medical technologies to make healthcare more accessible,” we are dedicated to innovation in the fields of Patient Monitoring & Life Support, In-Vitro Diagnostics and Medical Imaging Systems, amongst others.

Mindray possesses a sound global R&D, marketing and service network. Inspired by our customers’ needs, we adopt advanced technologies and transform them into accessible innovations that bring healthcare within reach across the world. While improving quality of care, we help reduce its cost, making it more accessible to a larger part of humanity.

Today, Mindray’s products and services are serving healthcare facilities in over 190 countries and regions.

Website: https://www.mindray.com
For four decades, Randox has led the way in diagnostics, offering pioneering solutions that simplify testing processes while maintaining high performance. Our portfolio includes our novel biochip technology, used in detecting conditions ranging from prostate and bladder cancer to Type 1 diabetes, showcases our dedication to advancing diagnostics. Randox Reagents provides a menu of over 100 assays for clinical chemistry analysis. Integrated into our portfolio, Our Acusera Quality Controls are crucial in ensuring accuracy and precision in test results. These controls undergo rigorous testing to meet stringent standards and deliver dependable results, empowering labs to confidently maintain testing accuracy. Randox is deeply committed to innovation, exemplified by our dedication to improving healthcare worldwide. Our goal is to ensure that laboratories have access to cutting-edge tools and technologies to address evolving healthcare needs.

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. In the Middle East, Roche offers comprehensive pharmaceutical and diagnostic expertise through the relevant and appropriate channels in 14 countries: Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Maldives, Oman, Palestine, Qatar, Saudi Arabia, Syria, United Arab Emirates, and Yemen.

For more information, please visit www.roche-middleeast.com
Website roche-middle east.com
Social Media
LinkedIn, Instagram and Meta

ARK Diagnostics Inc. develops, manufactures, and distributes in vitro diagnostic immunoassays for Therapeutic Drug Monitoring (TDM) and Urine Drug Testing (UDT). For TDM, clinicians use these measurements to guide dosing decisions for safe, effective, and personalized drug therapy. By optimizing drug levels, clinicians improve outcomes, reduce toxicity, and lower healthcare costs. For UDT, ARK has several unique assays for Fentanyl II, Pregabalin II, Gabapentin, and Methylphenidate Metabolite. Additionally, ARK has many other unique TDM and UDT Assays. ARK’s quality management system is certified to ISO 13485:2016. The company is committed to quality compliance and carefully follows Good Manufacturing Practices. ARK uses its unique blend of scientific expertise and deep industry knowledge to deliver high-quality assays for new generations of drugs. Its highly regarded homogeneous enzyme immunoassay technology is adaptable to a variety of clinical chemistry analyzers. Founded in 2003, ARK Diagnostics, Inc. is based in Fremont, California.

Established in 1998, Autobio Diagnostics Co., Ltd is a global leader in clinical diagnostics, specializing in immunoassay, microbiology, and biochemistry, while demonstrating a strong commitment to advancing molecular diagnostics for medical laboratories. With 25 years of R&D excellence, Autobio allocates over 14% of revenue to innovation. The extensive diagnostic antibody library covers tens of thousands of antigen epitopes, securing over 73% self-supply for a stable chain. Over a third of our workforce focuses on top-quality R&D. Autobio prioritizes not only product quality and sophisticated manufacturing but also customer satisfaction, ensuring superior service through a team of 800+ professional engineers worldwide. Thriving in 90+ countries, Autobio is dedicated to shaping the future of diagnostics globally. This dedication is mirrored in our expanding industrial park, covering 250 acres, which stands as a testament to our commitment to advancing international healthcare solutions.

Address:
Street: No.199, 15th Ave, National Eco&Tech Development Area, 450016 Zhengzhou, China
Phone: +86-371-6798-5313
Email: info@autobio-diagnostics.com
https://en.autobio.com.cn
COMPANY PROFILE

Babirus

Where Accuracy Meets Innovation in Healthcare Diagnostics.
Your Choice in Advancing Patient Care!
Babirus’ mission is to provide the most accurate and innovative diagnostics solutions to healthcare providers since 2008. The company achieves this by employing cutting-edge technology, expert personnel, and a commitment to continuous improvement.
Babirus is committed to working with healthcare partners across the MENA region to deliver innovative and advanced diagnostic solutions that help to improve people’s health. We believe that the key for helping medical specialists to improve patient outcomes is through a continuous program of medical education and trainings as well as offering ongoing scientific support from our highly dedicated and qualified team.
Babirus provides market leading and technologically innovative products from global healthcare companies, specialized in:
Babirus will always grow, profitability, continuity, and satisfaction of all its clients!

BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

For more information on BD, please visit www.bd.com or connect with us on LinkedIn at www.linkedin.com/company/bdx/ and Twitter @BDandCo.
Social media links:
https://www.linkedin.com/company/bdx
https://www.facebook.com/BectonDickinsonandCo
https://twitter.com/BDandCo
https://www.youtube.com/channel/UCPGrvtYj3EJp_3j2qNsn5a
BD (@becton_dickinson) • Instagram photos and videos

EXHIBITORS

BÜHLMANN

BÜHLMANN is a renowned in the field of quantitative fecal analysis, with a focus on calprotectin and pancreatic elastase. Demonstrated clinical reliability, supported by over 100 peer-reviewed studies, underpins our offerings. The Quantum Blue® rapid calprotectin, infliximab and adalimumab testing, offers efficient lateral flow analysis for immediate therapy adaptation in inflammatory diseases. Continuing our tradition of innovation, the BÜHLMANN fCAL® turbo assay provides streamlined workflow in modern lab environments with random access on clinical chemistry platforms for seamless integration into laboratory routine.
The innovative CALEX® stool preparation device ensures high-quality samples for quantitative fecal analysis, offering ease of use and limiting direct contact with stool. The design and the consequent separation of pre-analytics and analytics allows lay persons to collect, and lab staff are only required to integrate samples into the laboratory’s tracking systems. BÜHLMANN’s commitment to efficiency and precision sets the standard for cutting-edge solutions in laboratory diagnostics.
The Exhibiting COMPANY’s main fields of activity are:
• Development and manufacturing of unique immunoassays
• Distribution of in vitro diagnostic products

Address and Contact Details:
BÜHLMANN Laboratories AG
Baselstrasse 55 CH-4224 Schönenbuch
Phone +41 61 487 12 12 Fax +41 61 487 12 34
Email info@buhlmannlabs.ch
Web www.buhlmannlabs.ch

City Pharmacy

Established in 1967 by Dr. Abdulrahman Almahmeed, City Pharmacy Co. has dedicated itself to the advancement of Pharmaceutical & Health Care services in UAE.
Today, City Pharmacy Co. has proved beyond doubt that it has the resources, facilities, skills and vision leading towards the realization of this goal. Looking to the future, we are confident that we will be instrumental to the continued development of this success...so much so that we believe – the best is still yet to come! With over 50 years of expertise, City Pharmacy Co. Group is first of a kind in the growth of Pharmaceutical and Medical services in UAE. Our team of highly professional employees oversees every step in the process to ensure you receive the best quality service. City Pharmacy Co. has consistently achieved remarkable growth and today ranks No.1 in UAE’s market for pharmaceutical, medical and associated products and equipment.
https://www.citypharmacy.com/
Controllab is the largest Brazilian laboratory quality control company. Since 1977, our mission has been sowing quality and taking care of life. Our 47-year history is based on offering complete and integrated solutions in quality and assertiveness of laboratory results. With more than 3,500 tests, Controllab facilitates routine for laboratory accreditation processes and regulatory bodies. We are a full solution company in several segments: clinical, blood bank, veterinary, microbiology and physical-chemical tests for medicines, food, sanitizers, water and effluents, fuels and others, among services that serve hospitals and industries. Committed to improving user experience, we help clients to provide accurate, indisputable services and that stand out in the national and international markets. We have unique know-how in quality control solutions. We have the exclusive support of important scientific societies and the recognition of the main standards related to our performance: ISO 9001, 17025, 17034 and 17043.

Address and Contact Details:
Ana Neri street 416 - Benfica, Rio de Janeiro RJ, 20911-442, Brazil
Tel: +55 21 3891-9900 / +55 21 3613-5200
Website: https://controllab.com/en/

Dedalus is a leading healthcare and diagnostic software solutions provider globally, with over 30 years of experience in implementing successful laboratory solutions in over 5700 laboratories worldwide. Our comprehensive portfolio for the clinical laboratory offers the full range of Clinical Pathology, Anatomic Pathology, Digital Pathology, and Genetic solutions alongside result reporting, quality assurance, and Middleware software supporting laboratory and clinical professionals across the full diagnostic result generation chain, from patient admission or diagnostic request, sample verification, sample distribution to result reporting. Our goal is to enable precision medicine and optimal, interdisciplinary stakeholders’ decisions across the continuum of care, leveraging cloud, digital technologies, and AI to improve health outcomes. We advocate a fully integrated and patient-centered diagnostic system, enabling HCPs to leverage complex, ever-growing diagnostic testing data, to enhance care decisions at every stage of people’s lives. Leading us to be the partner of choice.

Address and Contact Details:
Barbara Francioni
Principal, Marketing – In Vitro Diagnostics Business Unit
M. +44 7507 487075
E. barbara.francioni@dedalus.com

DiAgam is a European company, with more than 30 years of experience, which manufactures Turbidimetric Specific Protein reagents. Our operations are ensured through our direct affiliates in Belgium, France, Spain, Portugal, and Brazil. We also export in ASEAN, EMAE, LATAM and US markets. Recognized as a very good quality assays, our leading innovative solutions are offered in user friendly instrument specific packaging for open chemistry systems from world leading instrument manufacturers including Abbott, Beckman Coulter, Siemens, Ortho Clinical Diagnostics or Roche®. These end-finished packaging kits save operator time and improve laboratory efficiency by eliminating reagent transfer. Our solutions are also available in OEM for any distributor which is looking for a high-quality Specific Protein reagents menu.

Menu:
- Albumin (immunological), Albumin in Csf, Alpha-1-acid glycoprotein, Alpha-1-antitrypsin, Alpha-1-macroglobulin, Beta-2-microglobulin, ApoA1, ApoB, ASO, Calprotectin, C3 C4, Ceruloplasmin, CRP, Haptoglobin, IgA, IgE, IgG, IgG in Csf, IgM, Lipoprotein(a), Microalbumin, Prealbumin, Rheumatoid Factor, RBP, Transferrin.

All products names, registered trademarks, company names in this document remain the property of their respective owners

DiaSys Diagnostic Systems - Diagnostic system solutions and service of outstanding quality! DiaSys GmbH has been a leading specialist in development and manufacturing of diagnostic system solutions for more than 30 years. Our goal is to combine high quality with ease of use and to reduce environmental burden. DiaSys has introduced more than 90 clinical chemistry and immunoturbidimetric reagents in user-friendly kits for manual or automated use. All reagents ensure reliable results in routine and special diagnostics. The instrumentation portfolio comprises automated clinical chemical analyzers for small to medium sized laboratories, semi-automated analyzers and POCT instruments. In addition, DiaSys offers a broad range of calibrators and quality control materials. DiaSys has been an ISO 13485-certified company since 1996. Customers and partners in more than 140 countries rely on the quality of DiaSys.

Address and Contact Details:
DiaSys Diagnostic Systems GmbH
Alte Strasse 9 - 65558 Holzheim, Germany
E-mail: mail@diasys.de
Phone: +49 6432 9146-0
Web: http://www.diasys-diagnostics.com
Disera was founded in 1996 in Izmir/Turkey and began with the production of laboratory consumables. Today, Disera is one of the leading international companies in the industry, specializing in the production and development of blood collection tubes including blood collection accessories, urine collection systems and PRP products. Disera is furthermore active in the laboratory diagnostics sector in its home market.

For us as a company, the patient’s comfort and healthcare workers safety come first. Our value proposition with our products and services is to improve the overall standard of living and health of the communities around the world.

As a producer of plastic medical products, we combine the production of high-quality products with an energy efficient and sustainable operation. Disera has its own solar power plant that supplies over 3 megawatts of electricity to all of the production facilities. In 2023, the first 20 kW/10MeV E-BEAM sterilization system in Turkey was put into operation by Disera.

Address and Contact Details:
575B Sok.No:4H /11, 35110 Karabağlar – İzmir/Türkiye.
info@disera.com.tr

Gelecek offers innovative and reliable preanalytical and post analytical solutions for low, medium and high volume laboratories and hospital’s blood collection services. With the solutions we offer under the Futurelab brand name, your preanalytical and post analytical operations are simplified, manual tasks and workload are reduced, and your productivity and quality increase. Our Solutions widely used hospitals and laboratories.

Address and Contact Details:
Tekнопark Istanbul Sanayi Mahallesi Teknopark Bulvarı 5A/107 34006 Pendik ISTANBUL
Contact mail : info@gelecekmuhendislik.com
Contact number : +902169996307
Website : www.gelecekmedikal.com

HVD Life Sciences is a marketing and distribution company that specializes in sourcing, supplying and supporting life science solutions. We bring a global perspective to our business worldwide, covering regions including Central and Southeast Europe, the Middle East, Africa, the Commonwealth of Independent States, and the Far East.

We offer a wide range of high quality products from carefully selected manufacturers of innovative and industry-leading tools and technologies. With all of our suppliers, we focus on building strong relationships that will ensure long-term success for our customers, our partners and ourselves.

Explore our portfolio online at www.hvdlifesciences.com

IVD Group Sp. z o.o. offers a complete solution for benchmark preanalytics. MedNAIS App is an iOS and Android application offering a library of guidelines for various sample types. Easy-to-follow step-by-step instructions accessible right on your smartphone or MedNAIS Smartwatch.

MedNAIS Smartwatch, designed specifically for medical nurses offering real-time assistance and efficiency enhancement through our specialized KPI analysis (patient turnaround time, exact sampling time and others). This innovative technology is designed to digitize preanalytical processes at their point of origin—in the sampling room.

MedNAIS Logger our advanced solution for logistics. Provides online reporting of transportation parameters (temperature, humidity, illuminance, vibration, GPS location), coupled with an automatic dispatch system for notifications. This ensures immediate action in case of non-compliance with transportation standards, guaranteeing the integrity of every sample.

Our largest online web shop IVD reagents and disposables of top brands available at https://ivdgroup.eu/products/. We are looking for suppliers!

Address Details:
info@samplify.org
https://samplify.org

Jedsy is a technology company based in Switzerland with the ultimate aim of designing and developing high-end multipurpose drones.

With the mission Delivery where it matters, when it matters, the company was founded in early 2021. Currently, Jedsy is making tremendous strides in the provision of healthcare, and emergency and courier services. Due to advanced and automated features, the Jedsy Glider (drone), is capable of delivering payload in tough terrains, distant areas, and destinations with poor infrastructure facilities with high success rate. Actually, Jedsy is the first company in the world to dock directly to a window or balcony with its delivery drone, making it even faster and easier to ship medical supplies.

Essentially, this is a sustainable and long-term solution to advancing efficiency, a critical aspect in saving human lives that would otherwise be lost if conventional methods were used.

https://jedsy.com
**Keyu Biological Engineering**

Zhuhai Keyu Biological Engineering Co., Ltd. (stock code: 870620) is a hi-tech service provider dedicated to R&D, manufacturing and sales of in vitro diagnostic analytical instruments and reagents. As a professional service provider of IVD and a leader in Automated Feces Analyzers, KEYU provides such products as Automated Urine Analyzers, Feces Analyzers, Leucorhea analyzers, and related reagents. Till now, we have more than 2,000 dealers and 3000 hospital clients worldwide, including 470+ 3A hospitals and 100+ ISO 15189-accredited medical laboratories.

**Address and Contact Details:**
Website: www.keyubio.com
Address: 1/f, 2/f, building 2, No.605, Yuge road, Sanzao town, Jinwan district, Zhuhai City, Guangdong Province, 519040, P.R.China

---

**Lifespin**

Lifespin GmbH is pushing the boundaries of personalized medicine, ensuring its position at the forefront of the industry with a commitment to enhancing patient care through technological excellence.

**Address and Contact Details:**
Website: www.lumiradx.com
Tel.: +353 83 449 0378
Mr. Paul Campbell
For more information, please visit www.lumiradx.com.

LumiraDx is transforming community-based healthcare by providing fast, accurate and comprehensive diagnostic information at the point of need, enabling better medical decisions that lead to improved outcomes at a lower cost. The company’s innovative LumiraDx Platform is designed to perform a broad menu of tests including infectious disease, cardiovascular disease, diabetes, and coagulation disorders and deliver lab-comparable performance with results in less than 12 minutes. Founded in 2014, LumiraDx is based in the UK with R&D and manufacturing sites across the US and Europe. For more information, please visit www.lumiradx.com.

**Address and Contact Details:**
Mr. Paul Campbell
Global Product Director, Cardiometabolic
Unit 4 Block 3 Manor Farm Business Park, Manor Long, Stirling FK9 5QD - UK
Tel.: +353 83 449 0378
Website: https://www.lumiradx.com/

---

**Maccura**

Maccura was founded in 1994 and has been focusing on the research, manufacture, marketing, and services of IVD products. Maccura is a hi-tech enterprise certified by related national departments and has passed not only the certification of CMD ISO13485, CCC ISO14001, TUV ISO13485, but also the CE certification for some products. We have a world-class R&D, manufacture and operation team, have completed the layout of whole industrial chain from biological raw materials, medical laboratory products to professional services, and have the systematic ability to research and manufacture IVD instruments, reagents, calibrators and control materials.

Our products have covered platforms of biochemistry, immunoassay, POCT, hematology, molecular diagnosis and pathology, and could meet more than 90% requirements of medical labs with the product integration.

With the corporate vision of “To be a World-Class IVD Enterprise”, we provide quality products and services to our customers by concentrating on technology innovation.

**Address and Contact Details:**
Dean Zhao  +86 138-8069-2324
dean.zhao@maccura.cn
16#, Baichuan Road, Hi-tech Zone, 611731 Chengdu, China

---

**MassSpec Medical**

MassSpec Medical is a new company founded by mass spectroscopy senior scientists, life and medical science researchers, clinical microbiologists and IT specialists. We use (modified) immunoassay in mass spectroscopy and mass spectroscopy in immunoassay resulting in ultimate specificity, good sensitivity, multiplexing options, high throughput and speed as well as ease of use and low cost.

In bacteriology, we offer our proprietary bacterial wall polysaccharide profiling and in silico protein/peptide libraries.

---

**Nephrolyx**

Nephrolyx offers precise and rapid measurement of kidney function (True GFR). We provide laboratories and hospitals with an In-Vitro Diagnostic Test (Nephrolyx IVDx) and a digital platform. This CE-certified, ready-to-use solution allows for precise renal function measurement (mgFR) in just a few hours, easily integrating into clinical routines. For the first time, physicians can diagnose renal diseases with unparalleled accuracy, enabling them to utilize precision medicine and develop optimal treatment plans for patients. This is especially beneficial for patients in nephrology, oncology, transplantation, and ICU settings. The Nephrolyx IVDx utilizes in-vitro quantitative determination of serum iohexol concentration, recognized as the highest accuracy gold standard by the EMA, FDA, and the 2024 KDIGO CKD guidelines. Nephrolyx’s proprietary technology enhances treatment outcomes for patients. Given its low component cost, the Nephrolyx True GFR Measurement can also significantly enhance the performance of the entire healthcare system.

**Address and Contact Details:**
Nephrolyx GmbH
Johann-Hittorf-Straße 8 - 12489 Berlin - Germany
www.nephrolyx.com - contact@nephrolyx.com

---
**COMPANY PROFILE**

**Neurocode**

Neurocode’s pioneering assay measures levels of phosphorylated tau at position 217 (pTau217). pTau217 is widely considered to be the leading transformative blood-based biomarker that will enable earlier and more accurate AD diagnosis, improved patient care and treatment. The introduction of new compounds in represents a significant advancement in disease-modifying therapy of Alzheimer’s disease will change the trajectory. We will offer this test shortly in several counties around the world.

Neurocode is a clinical laboratory that offers novel and innovative FDA-approved and laboratory-developed tests, specializing in neurodegeneration and neuroimmunology biomarkers for clinical and research use. They work closely with researchers to advance the field of AD diagnostics and perform thorough validations of novel biomarkers to empower clinicians to make informed decisions. To learn more about accessing the ALZpath Dx test and Neurocode’s full range of diagnostic solutions, please visit neurocode.com or info@neurocode.com contact us below:

**Address and Contact Details:**
3560 Meridian, Suite 101 | Bellingham, WA 98225, USA | +1 425-312-3791 | +1 360-527-4596 (Fax) | CustomerCare@neurocode.com | neurocode.com

---

**Novo Biomedical**

Nova, a world leader in point of care (POC) and critical care in-vitro diagnostics, offers the following products:

- **Stat Profile Prime Plus®** blood gas critical care analyzers offer the most clinical value for critical care testing with a 24-test menu and important new tests for iMg, estimated plasma volume (ePV), Urea, Creatinine. StatStrip® Glucose/Ketone offers lab-like accuracy for testing critically ill patients while eliminating interferences from ascorbic acid, hematocrit, maltose, oxygen, and other substances. StatStrip® Lactate/Hb & Hct offers rapid screening and monitoring of sepsis or for use as an alternative to fetal scalp pH testing. the Hb & Hct strip provides a rapid anemia assessment. StatSensor® and Nova Max Pro eGFR meters measure capillary blood creatinine and calculate eGFR for rapid renal function screening or assessment prior to using contrast media. Allegra® is a compact blood capillary blood analyzer that measures HbA1c, Lipids, Glucose, Creatinine, CRP, PT/INR and urine albumin/creatinine using disposable cartridges and test strips. EMS Stat™ is a portable system for A&E use for rapid glucose, ketone, lactate, hemoglobin, and hematocrit testing using tiny capillary blood samples.

**Address and Contact Details:**
Nova Biomedical
200 Prospect Street, Waltham, Massachusetts 02454 USA
Tel. 781-894-0800 - Fax. 781-894-5915
Email. info@novabiomedical.com
Web site. www.novabiomedical.com

---

**RfB/SPMD**

RfB/SPMD – Quality assurance for medical laboratories
RfB/SPMD stands as a global leader in quality assurance solutions for medical laboratories, underpinned by its own accredited calibration laboratories in accordance with DIN ISO/IEC 17025 and DIN EN ISO 15195 standards. Our surveys, spanning over 730 analytes in laboratory medicine, serve participants worldwide and are conducted in German and English. Using web-based platforms, from order placement to result submission and certificate delivery, our surveys are seamlessly conducted online through our web portal. Accredited according to DIN EN ISO/IEC 17043 we maintain unwavering commitment to stringent quality standards. Additionally, our surveys are supported by reference laboratories, further enhancing the accuracy and reliability of our assessments. This integrated approach ensures that laboratories worldwide receive the highest quality assurance services, reinforcing confidence in their processes and results. Proudly “made in Germany,” RfB/SPMD epitomizes excellence in laboratory quality assurance on a global scale.

---

**Sansure Biotech Inc.**

Sansure Biotech Inc. is an in vitro diagnostic all-round solution provider that integrates diagnostic reagents, instruments, and independent clinic laboratory services with innovative gene technology as its core. The company is listed on the Chinese Science and Technology Innovation Board and has ranked in the Top 100 Healthcare Company in China for 3 consecutive years. Sansure has developed more than 1000 test kits/reagents covering 6 major fields: prevention and control of infectious disease diagnosis, health care for women and children’s health, blood transfusion safety, prevention and control of cancer, companion diagnostics, agriculture and animal husbandry technology, etc.

As a leading Chinese molecular diagnostic enterprise, Sansure is accelerating its transformation into a global leader in in-vitro diagnostics and striving to create high-quality products.

**Address and Contact Details:**
Sansure Biotech
China - Zhejiang, Hangzhou
Tel. +86-571-8121-8888
Fax. +86-571-8121-8828
Email. info@sansure.com
Web site. www.sansure.com
Waters Corporation unlocks the potential of science by providing the tools, technology and insights that enable scientific breakthroughs in labs across the globe. For over 60 years, Waters has provided high-value analytical technologies and industry leading scientific expertise, with solutions that serve life, materials, and food sciences. Having pioneered innovations in chromatography, mass spectrometry, and thermal analysis, the company operates a robust business model with instruments, software, service, and other recurring revenues. With its diverse, global footprint, Waters serves high volume segments in resilient end-markets where routine analysis is often required to meet quality standards and regulatory requirements. This includes:

- Pharmaceutical development and manufacturing quality
- Food, water, and environmental testing
- Materials analysis, including battery characterization and testing for electric vehicles.

In practice, our instruments and software ensure the safety of the medicines we take, the purity of the food and water we consume, and the quality and durability of products we use every day. With approximately 7,900 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.

Weqas is one of the leading External Quality Assessment (EQA) providers with over 50 years’ experience in Quality Assurance, providing solutions in Laboratory Medicine. We have expert teams of scientists delivering service in Laboratory EQA, Point of Care (PoCT) EQA, Reference Measurement Services, Internal Quality Control (IQC), Quality Control Reference Material (QCRM) Service, and Education and Training Services.

Benefits of working with Weqas:
1. Accredited to ISO 17043, 17025 and 15195.
2. Over 50 EQA programmes.
3. Access to EQA participant portal to allow easy monitoring of instrument performance.
5. Standard and bespoke IQC and QCRM.

Shenzhen YHLO Biotech Co., Ltd. YHLO (EST. 2008) is an innovative company of immunoassay solutions headquartered in Shenzhen, China, specialized in developing, manufacturing IVD instruments and reagents. To be a reliable and respected IVD enterprise, YHLO has put extensive investments in R&D and firmly associated with top universities and research institutes worldwide on scientific studies. With over a decade’s continuous development expertise in immunoassay solution, YHLO may provide a broad range of instruments with patented technologies and outstanding features, as well as a comprehensive total solutions in fertility and reproductive health, infectious diseases, autoimmune disorders and other novel assays on rare diseases analysis.

To date, YHLO has a global presence by over 110 countries and regions worldwide. Moreover, YHLO has in-depth cooperation with oversea research partners in Europe, USA, Japan and Australia, with aim of developing advanced technologies and create more medical value for health and vitality of people all over the world.

Address and Contact Details:
Pine Lin
008613691865720
paul.lin@szyhlo.com
Shenzhen Longgang District Baolong Street Baolong Road Yahuilong Biotech Park